<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><front><journal-meta><journal-id journal-id-type="nlm-ta">Multidiscip Respir Med</journal-id><journal-id journal-id-type="iso-abbrev">Multidiscip Respir Med</journal-id><journal-title-group><journal-title>Multidisciplinary Respiratory Medicine</journal-title></journal-title-group><issn pub-type="ppub">1828-695X</issn><issn pub-type="epub">2049-6958</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23800154</article-id><article-id pub-id-type="pmc">3707735</article-id><article-id pub-id-type="publisher-id">2049-6958-8-40</article-id><article-id pub-id-type="doi">10.1186/2049-6958-8-40</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title>Effects of nutraceutical diet integration, with coenzyme Q<sub>10</sub> (Q-Ter multicomposite) and creatine, on dyspnea, exercise tolerance, and quality of life in COPD patients with chronic respiratory failure</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Marinari</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>stefanomarinari@alice.it</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Manigrasso</surname><given-names>Maria Rosaria</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mrmanigrasso@libero.it</email></contrib><contrib contrib-type="author" id="A3"><name><surname>De Benedetto</surname><given-names>Fernando</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>debened@unich.it</email></contrib></contrib-group><aff id="I1"><label>1</label>Pneumology Department, SS Annunziata Hospital, Chieti, Italy</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>21</day><month>6</month><year>2013</year></pub-date><volume>8</volume><issue>1</issue><fpage>40</fpage><lpage>40</lpage><history><date date-type="received"><day>13</day><month>3</month><year>2013</year></date><date date-type="accepted"><day>6</day><month>6</month><year>2013</year></date></history><permissions><copyright-statement>Copyright © 2013 Marinari et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Marinari et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.mrmjournal.com/content/8/1/40"></self-uri><abstract><sec><title><offsets xml_i="3212" xml_f="3222" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3233" xml_f="3453" txt_i="22" txt_f="242">The protein-calorie malnutrition, resulting in muscle mass loss, frequently occurs in severe COPD patients with chronic respiratory failure (CRF), causing dyspnea, reduced exercise tolerance and impaired quality of life.</offsets></p><p><offsets xml_i="3460" xml_f="3644" txt_i="243" txt_f="427">The cause of this occurrence is an intake-output energy imbalance. A documented deficit of phosphocreatine and reduced mithocondrial energy production can contribute to this imbalance.</offsets></p><p><offsets xml_i="3651" xml_f="3910" txt_i="428" txt_f="687">Aim of this study is to verify whether a dietary supplementation with creatine and coenzyme Q10, important mitochondrial function factors, is able to influence this mechanism leading to a dyspnea reduction and improving exercise tolerance and quality of life.</offsets></p></sec><sec><title><offsets xml_i="3932" xml_f="3939" txt_i="689" txt_f="696">Methods</offsets></title><p><offsets xml_i="3950" xml_f="4015" txt_i="697" txt_f="762">55 COPD patients with chronic respiratory failure (in long term O</offsets><sub><offsets xml_i="4020" xml_f="4021" txt_i="762" txt_f="763">2</offsets></sub><offsets xml_i="4027" xml_f="4348" txt_i="763" txt_f="1084"> therapy), in stable phase of the disease and without severe comorbidities were assigned (double-blind, randomized) to: group A (30 patients) with daily dietary supplementation with Creatine 340 mg + 320 mg Coenzyme Q-Ter (Eufortyn®, Scharper Therapeutics Srl) for 2 months whereas Group B (25 patients) received placebo.</offsets></p><p><offsets xml_i="4355" xml_f="4833" txt_i="1085" txt_f="1563">All patients continued the same diet, rehabilitation and therapy during the study. At recruitment (T0) and after 2 months (T1), patients were submitted to medical history, anthropometry (BMI), bioelectrical impedance, arterial blood gas analysis, evaluation of dyspnea (VAS, Borg, BDI, MRC) and functional independence (ADL), 6-minute walk test (6MWT) and quality of life questionnaire (SGRQ). At 6 months and 1 year, a telephone follow up was conducted on exacerbations number.</offsets></p></sec><sec><title><offsets xml_i="4855" xml_f="4862" txt_i="1565" txt_f="1572">Results</offsets></title><p><offsets xml_i="4873" xml_f="5776" txt_i="1573" txt_f="2452">No significant difference was detected at baseline (T0) in the 2 groups. After 2 months of therapy (T1) the FFMI increased in the daily dietary supplementation group (+ 3.7 %) and decreased in the placebo group (- 0.6 %), resulting in a statistically significant (p &lt; 0.001) treatment difference. Statistically significant treatment differences, favouring daily dietary supplementation group, were also seen for the 6MWT comparison. Group A patients also showed significant: 1) improvement in the degree of dyspnea (VAS: p &lt; 0.05; Borg: p &lt; 0.05; MRC: p &lt; 0.001; BDI1: p &lt; 0.05; BDI3: p &lt; 0.03), and independence level in activities of daily living (p &lt; 0.03); 2) improvement in quality of life in activity section (- 6.63 pt) and in total score (- 5.43 pt); 3) exacerbation number decrease (p &lt; 0.02). No significant differences were found (end of study vs baseline) in group B.</offsets></p></sec><sec><title><offsets xml_i="5798" xml_f="5809" txt_i="2454" txt_f="2465">Conclusions</offsets></title><p><offsets xml_i="5820" xml_f="5910" txt_i="2466" txt_f="2556">The nutraceutical diet integration with Q-Ter and creatine, in COPD patients with CRF in O</offsets><sub><offsets xml_i="5915" xml_f="5916" txt_i="2556" txt_f="2557">2</offsets></sub><offsets xml_i="5922" xml_f="6207" txt_i="2557" txt_f="2842">TLT induced an increasing lean body mass and exercise tolerance, reducing dyspnea, quality of life and exacerbations. These results provide a first demonstration that acting on protein synthesis and muscular efficiency can significantly modify the systemic consequences of the disease.</offsets></p></sec></abstract><kwd-group><kwd>Chronic respiratory failure</kwd><kwd>Coenzyme Q<sub>10</sub></kwd><kwd>COPD</kwd><kwd>Creatine</kwd><kwd>Dyspnea</kwd><kwd>Exercise tolerance</kwd><kwd>Q-Ter</kwd><kwd>Quality of life</kwd></kwd-group></article-meta></front><body><sec><title><offsets xml_i="6487" xml_f="6497" txt_i="2851" txt_f="2861">Background</offsets></title><p><offsets xml_i="6508" xml_f="6669" txt_i="2862" txt_f="3023">Several studies demonstrated the prognostic importance of body weight and protein-calorie malnutrition in Chronic Obstructive Pulmonary Disease (COPD) patients [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="6700" xml_f="6701" txt_i="3023" txt_f="3024">1</offsets></xref><offsets xml_i="6708" xml_f="6709" txt_i="3024" txt_f="3025">-</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="6740" xml_f="6741" txt_i="3025" txt_f="3026">4</offsets></xref><offsets xml_i="6748" xml_f="6895" txt_i="3026" txt_f="3173">], so that malnutrition is an important component of “systemic” problems of international guidelines for the management and the treatment of COPD [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="6926" xml_f="6927" txt_i="3173" txt_f="3174">5</offsets></xref><offsets xml_i="6934" xml_f="6935" txt_i="3174" txt_f="3175">,</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="6966" xml_f="6967" txt_i="3175" txt_f="3176">6</offsets></xref><offsets xml_i="6974" xml_f="6976" txt_i="3176" txt_f="3178">].</offsets></p><p><offsets xml_i="6983" xml_f="7271" txt_i="3179" txt_f="3467">Over 25 years ago the first observations of this phenomenon showed the high prevalence of underweight status among patients with severe disease, while later studies evidenced the importance of assessing lean body mass reduction often in presence of normal and even increased body weight [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="7302" xml_f="7303" txt_i="3467" txt_f="3468">7</offsets></xref><offsets xml_i="7310" xml_f="7311" txt_i="3468" txt_f="3469">,</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="7342" xml_f="7343" txt_i="3469" txt_f="3470">8</offsets></xref><offsets xml_i="7350" xml_f="7352" txt_i="3470" txt_f="3472">].</offsets></p><p><offsets xml_i="7359" xml_f="7503" txt_i="3473" txt_f="3617">The principal metabolic causes of malnutrition are: inadequate caloric intake, increased energy expenditure and alteration of protein turnover [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="7534" xml_f="7535" txt_i="3617" txt_f="3618">9</offsets></xref><offsets xml_i="7542" xml_f="7543" txt_i="3618" txt_f="3619">-</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="7575" xml_f="7577" txt_i="3619" txt_f="3621">20</offsets></xref><offsets xml_i="7584" xml_f="7586" txt_i="3621" txt_f="3623">].</offsets></p><p><offsets xml_i="7593" xml_f="7860" txt_i="3624" txt_f="3891">Moreover the presence of hypoxemia in patients with COPD could determine muscular inefficiency through: reduced muscles aerobic capacity (greater use of anaerobic energy sources, aerobic muscular enzymes reduction, earlier metabolic acidosis) and reduced peripheral O</offsets><sub><offsets xml_i="7865" xml_f="7866" txt_i="3891" txt_f="3892">2</offsets></sub><offsets xml_i="7872" xml_f="7941" txt_i="3892" txt_f="3961"> use (alteration of red blood transport cells/mitochondria, altered O</offsets><sub><offsets xml_i="7946" xml_f="7947" txt_i="3961" txt_f="3962">2</offsets></sub><offsets xml_i="7953" xml_f="8039" txt_i="3962" txt_f="4048"> distribution between operating muscle fibers, cellular oxidative processes inertia) [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="8071" xml_f="8073" txt_i="4048" txt_f="4050">21</offsets></xref><offsets xml_i="8080" xml_f="8082" txt_i="4050" txt_f="4052">].</offsets></p><p><offsets xml_i="8089" xml_f="8240" txt_i="4053" txt_f="4204">The effects of these mechanisms on COPD patients’ muscles are on the basis of exercise tolerance reduction, dyspnea increase and poor quality of life [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="8272" xml_f="8274" txt_i="4204" txt_f="4206">22</offsets></xref><offsets xml_i="8281" xml_f="8282" txt_i="4206" txt_f="4207">-</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="8314" xml_f="8316" txt_i="4207" txt_f="4209">27</offsets></xref><offsets xml_i="8323" xml_f="8442" txt_i="4209" txt_f="4328">]. Interesting confirmations come from muscular biopsies that showed alterations in number and mitochondrial function [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="8474" xml_f="8476" txt_i="4328" txt_f="4330">28</offsets></xref><offsets xml_i="8483" xml_f="8484" txt_i="4330" txt_f="4331">-</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="8516" xml_f="8518" txt_i="4331" txt_f="4333">32</offsets></xref><offsets xml_i="8525" xml_f="8899" txt_i="4333" txt_f="4707">]. Furthermore, studies on muscle metabolism, trough P31-NMR on peripheral muscle, showed an increase in enzymes activity involved in anaerobic glycolysis and reduction of enzymes involved in the oxidative chain. Low concentrations of high energy phosphates (phosphocreatine, ATP-AMP) at rest and slow deposits recovery of phosphocreatine after exercise have been reported [</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="8931" xml_f="8933" txt_i="4707" txt_f="4709">33</offsets></xref><offsets xml_i="8940" xml_f="8941" txt_i="4709" txt_f="4710">,</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="8973" xml_f="8975" txt_i="4710" txt_f="4712">34</offsets></xref><offsets xml_i="8982" xml_f="9087" txt_i="4712" txt_f="4817">]. Other studies, conducted in chronic diseases such as COPD, demonstrated a deficit of elements such as </offsets><bold><offsets xml_i="9093" xml_f="9094" txt_i="4817" txt_f="4818">c</offsets></bold><offsets xml_i="9101" xml_f="9110" txt_i="4818" txt_f="4827">oenzyme Q</offsets><sub><offsets xml_i="9115" xml_f="9117" txt_i="4827" txt_f="4829">10</offsets></sub><offsets xml_i="9123" xml_f="9358" txt_i="4829" txt_f="5064"> or ubiquinone, which is an essential element for the mitochondrion function that promotes the production of ATP and energy. It is normally synthesized endogenously, but it is frequently reduced in the elderly and in chronic diseases [</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="9390" xml_f="9392" txt_i="5064" txt_f="5066">35</offsets></xref><offsets xml_i="9399" xml_f="9401" txt_i="5066" txt_f="5068">].</offsets></p><p><offsets xml_i="9408" xml_f="9516" txt_i="5069" txt_f="5177">Based on these assumptions, dietary supplementation studies have been performed with creatine and coenzyme Q</offsets><sub><offsets xml_i="9521" xml_f="9523" txt_i="5177" txt_f="5179">10</offsets></sub><offsets xml_i="9529" xml_f="9616" txt_i="5179" txt_f="5266"> in patients with COPD or chronic heart failure. In particular, creatine and coenzyme Q</offsets><sub><offsets xml_i="9621" xml_f="9623" txt_i="5266" txt_f="5268">10</offsets></sub><offsets xml_i="9629" xml_f="9721" txt_i="5268" txt_f="5360"> seem to have a key role in improving protein turnover and mitochondrial energy production [</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="9753" xml_f="9755" txt_i="5360" txt_f="5362">36</offsets></xref><offsets xml_i="9762" xml_f="9763" txt_i="5362" txt_f="5363">-</offsets><xref ref-type="bibr" rid="B40"><offsets xml_i="9795" xml_f="9797" txt_i="5363" txt_f="5365">40</offsets></xref><offsets xml_i="9804" xml_f="9806" txt_i="5365" txt_f="5367">].</offsets></p><p><offsets xml_i="9813" xml_f="9920" txt_i="5368" txt_f="5475">Aim of this study is to demonstrate that, in a group of COPD patients with chronic respiratory failure in O</offsets><sub><offsets xml_i="9925" xml_f="9926" txt_i="5475" txt_f="5476">2</offsets></sub><offsets xml_i="9932" xml_f="9972" txt_i="5476" txt_f="5516"> home therapy, a dietary supplement (CoQ</offsets><sub><offsets xml_i="9977" xml_f="9979" txt_i="5516" txt_f="5518">10</offsets></sub><offsets xml_i="9985" xml_f="10075" txt_i="5518" txt_f="5608"> + creatine) is able to reduce dyspnea and improve exercise tolerance and quality of life.</offsets></p><sec><title><offsets xml_i="10091" xml_f="10111" txt_i="5609" txt_f="5629">Subjects and methods</offsets></title><sec><title><offsets xml_i="10131" xml_f="10139" txt_i="5630" txt_f="5638">Subjects</offsets></title><p><offsets xml_i="10150" xml_f="10232" txt_i="5639" txt_f="5721">We enrolled clinically stable COPD patients with chronic respiratory failure, in O</offsets><sub><offsets xml_i="10237" xml_f="10238" txt_i="5721" txt_f="5722">2</offsets></sub><offsets xml_i="10244" xml_f="10320" txt_i="5722" txt_f="5798"> therapy for at least 3 years and with an optimized pharmacological therapy.</offsets></p><p><offsets xml_i="10327" xml_f="10625" txt_i="5799" txt_f="6097">The patients met the following inclusion criteria: patients aged ≥ 60 ≤ 85 years, without exacerbations and hospitalizations (for any reason) in the last month, who could give informed consent were included. During the study, subjects maintained a constant diet and drug therapy (including oxygen).</offsets></p><p><offsets xml_i="10632" xml_f="11168" txt_i="6098" txt_f="6634">Exclusion criteria were as follows: smoking habits, home mechanical ventilation, presence of comorbidities such as diabetes, severe heart failure (NYHA 3 and 4), severe renal or hepatic impairment, active or recent neoplastic disease (no cancer treatment for at least 3 years), chronic infections (TB, HIV, serious structural disease of the lungs), chronic systemic steroid therapy, other diseases that could prevent execution of tests according to the study protocol (inability to walk , inability to perform functional testing, etc…).</offsets></p></sec></sec></sec><sec sec-type="methods"><title><offsets xml_i="11221" xml_f="11228" txt_i="6638" txt_f="6645">Methods</offsets></title><p><offsets xml_i="11239" xml_f="11396" txt_i="6646" txt_f="6803">The study protocol described above was approved by the Ethics Committee of "G. D'Annunzio" University of Chieti and Pescara and ASL2 Lanciano, Vasto, Chieti.</offsets></p><p><offsets xml_i="11403" xml_f="11578" txt_i="6804" txt_f="6979">In patients who met the inclusion criteria and who provided their written informed consent, at baseline (T0) were done: 1) medical history questionnaire on COPD, duration of O</offsets><sub><offsets xml_i="11583" xml_f="11584" txt_i="6979" txt_f="6980">2</offsets></sub><offsets xml_i="11590" xml_f="11951" txt_i="6980" txt_f="7341"> therapy , number of exacerbations, defined as a rapid change in clinical symptoms of such intensity to require the use of antibiotics and/or systemic steroids, number of hospitalizations in the last year and presence of comorbidities; 2) calculation of Body Mass Index (BMI); 3) complete lung function study: static and dynamic lung volumes, lung diffusion (DL</offsets><sub><offsets xml_i="11956" xml_f="11958" txt_i="7341" txt_f="7343">CO</offsets></sub><offsets xml_i="11964" xml_f="12184" txt_i="7343" txt_f="7563">) (Sensormedics, VMAX); 4) arterial blood gas analysis (ABL 700 series – Radiometer Copenaghen); 5) bioimpendence analysis of body composition (BIA 101, AKERN ) for the evaluation of Fat Free Mass Index (FFMI: FFM/height</offsets><sup><offsets xml_i="12189" xml_f="12190" txt_i="7563" txt_f="7564">2</offsets></sup><offsets xml_i="12196" xml_f="12199" txt_i="7564" txt_f="7567">) [</offsets><xref ref-type="bibr" rid="B41"><offsets xml_i="12231" xml_f="12233" txt_i="7567" txt_f="7569">41</offsets></xref><offsets xml_i="12240" xml_f="12517" txt_i="7569" txt_f="7846">]; 6) assessment of the degree of resting dyspnea (Medical Research Council - MRC scale and Baseline Dyspnea Index - BDI scale); 7) evaluation of exertional dyspnea (Borg scale, VAS) and measurement of activities of daily living (questionnaire: activities daily living - ADL) [</offsets><xref ref-type="bibr" rid="B42"><offsets xml_i="12549" xml_f="12551" txt_i="7846" txt_f="7848">42</offsets></xref><offsets xml_i="12558" xml_f="12647" txt_i="7848" txt_f="7937">]; 8) evaluation of exercise capacity (6MWT), according to ATS document, March 2002) in O</offsets><sub><offsets xml_i="12652" xml_f="12653" txt_i="7937" txt_f="7938">2</offsets></sub><offsets xml_i="12659" xml_f="12669" txt_i="7938" txt_f="7948"> therapy [</offsets><xref ref-type="bibr" rid="B43"><offsets xml_i="12701" xml_f="12703" txt_i="7948" txt_f="7950">43</offsets></xref><offsets xml_i="12710" xml_f="12805" txt_i="7950" txt_f="8045">]; 9) evaluation of the quality of life using Saint George's Respiratory Questionnaire (SGRQ) [</offsets><xref ref-type="bibr" rid="B44"><offsets xml_i="12837" xml_f="12839" txt_i="8045" txt_f="8047">44</offsets></xref><offsets xml_i="12846" xml_f="12848" txt_i="8047" txt_f="8049">].</offsets></p><p><offsets xml_i="12855" xml_f="13099" txt_i="8050" txt_f="8294">Thirty patients received, in double-blind randomized, daily dietary oral supplementation with Creatine 340 mg + 320 mg Coenzyme Q-Ter (Eufortyn®, Scharper Therapeutics Srl) for 2 months (Group A), whereas 25 patients received placebo (Group B).</offsets></p><p><offsets xml_i="13106" xml_f="13451" txt_i="8295" txt_f="8640">At time T1 (2 months after the start of therapy) the following parameters were re-evaluated: arterial blood gases analysis, bioimpedence analysis, assessment of the degree of dyspnea at rest and after exercise (VAS, Borg, BDI, MRC) and functional independence (Activities of Daily Living - ADL), 6MWT , and quality of life questionnaire (SGRQ) [</offsets><xref ref-type="bibr" rid="B44"><offsets xml_i="13483" xml_f="13485" txt_i="8640" txt_f="8642">44</offsets></xref><offsets xml_i="13492" xml_f="13494" txt_i="8642" txt_f="8644">].</offsets></p><p><offsets xml_i="13501" xml_f="13661" txt_i="8645" txt_f="8805">After 10 months from the end of therapy, all patients were subjected to a follow up telephone questionnaire on the number of exacerbations in the previous year.</offsets></p><sec><title><offsets xml_i="13677" xml_f="13689" txt_i="8806" txt_f="8818">Study design</offsets></title><p><offsets xml_i="13700" xml_f="13917" txt_i="8819" txt_f="9036">It was a randomized, double-blind versus placebo study. The treatments were: Creatine 170 mg + 160 mg Coenzyme Q-Ter (EufortynLios), 2 times a day for 2 months (Group A) or placebo bags apparently identical (Group B).</offsets></p></sec><sec><title><offsets xml_i="13939" xml_f="13959" txt_i="9038" txt_f="9058">Statistical analysis</offsets></title><p><offsets xml_i="13970" xml_f="15195" txt_i="9059" txt_f="10284">Statistical analysis was performed by using the SAS (version 9.2) statistical package. The sample size estimate was based on the results of a previous pilot study, assuming a difference of 2.0 % (standard deviation 2.5 %) between groups (daily dietary supplementation versus placebo) for the primary efficacy variable (Free Fat Mass Index) when analyzed with the analysis of covariance (ANCOVA). With normally distributed data and a two-sided α = 0.05, 30 subjects per group were needed to achieve a statistical power of 85% for the primary outcome measure. The safety sample was defined as all subjects who provided consent, were randomized, and it had at least one dose of daily dietary supplementation or placebo. The primary efficacy analysis was performed on the full analysis sample: all subjects in the safety sample who had at least one post-baseline efficacy measurement. Descriptive statistics, mean and standard deviation (SD), were reported for baseline (T0) demographic characteristics and efficacy outcome measures. The primary outcome measure (FFMI) mean was compared between treatment groups using ANCOVA, with the baseline value as a covariate and treatment as a factor. Significance was estimated using the </offsets><italic><offsets xml_i="15203" xml_f="15204" txt_i="10284" txt_f="10285">F</offsets></italic><offsets xml_i="15213" xml_f="15492" txt_i="10285" txt_f="10564">-test at the 5% level. ANCOVA was also performed as an exploratory analysis for the 6MWT comparison between treatment groups. The statistical significance of changes in all efficacy outcomes from baseline to the end of the double-blind phase was assessed using the Paired Sample </offsets><italic><offsets xml_i="15500" xml_f="15501" txt_i="10564" txt_f="10565">t</offsets></italic><offsets xml_i="15510" xml_f="15540" txt_i="10565" txt_f="10595">-Test (exploratory analysis). </offsets><italic><offsets xml_i="15548" xml_f="15549" txt_i="10595" txt_f="10596">p</offsets></italic><offsets xml_i="15558" xml_f="15596" txt_i="10596" txt_f="10631"> &lt; 0.05 was considered significant.</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="15643" xml_f="15650" txt_i="10634" txt_f="10641">Results</offsets></title><p><offsets xml_i="15661" xml_f="15916" txt_i="10642" txt_f="10897">The baseline comparison (T0) between the patient’s characteristics of the two groups didn’t show any significant difference concerning: age, body mass index (BMI), Free-fat mass index (FFMI), arterial blood gas levels in ambient air (partial pressure of O</offsets><sub><offsets xml_i="15921" xml_f="15922" txt_i="10897" txt_f="10898">2</offsets></sub><offsets xml_i="15928" xml_f="15933" txt_i="10898" txt_f="10903">, PaO</offsets><sub><offsets xml_i="15938" xml_f="15939" txt_i="10903" txt_f="10904">2</offsets></sub><offsets xml_i="15945" xml_f="15969" txt_i="10904" txt_f="10928">, partial pressure of CO</offsets><sub><offsets xml_i="15974" xml_f="15975" txt_i="10928" txt_f="10929">2</offsets></sub><offsets xml_i="15981" xml_f="15987" txt_i="10929" txt_f="10935">, PaCO</offsets><sub><offsets xml_i="15992" xml_f="15993" txt_i="10935" txt_f="10936">2</offsets></sub><offsets xml_i="15999" xml_f="16112" txt_i="10936" txt_f="11049">), respiratory function parameters such as forced vital capacity (FVC), forced expiratory volume in 1 second (FEV</offsets><sub><offsets xml_i="16117" xml_f="16118" txt_i="11049" txt_f="11050">1</offsets></sub><offsets xml_i="16124" xml_f="16187" txt_i="11050" txt_f="11113">), residual volume (RV), lung diffusion for carbon monoxide (DL</offsets><sub><offsets xml_i="16192" xml_f="16194" txt_i="11113" txt_f="11115">CO</offsets></sub><offsets xml_i="16200" xml_f="16311" txt_i="11115" txt_f="11226">), degree of dyspnea measured by Medical Research Council (MRC) scale and 6 min walking distance (6MWD) (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="16343" xml_f="16344" txt_i="11226" txt_f="11227">1</offsets></xref><offsets xml_i="16351" xml_f="16353" txt_i="11227" txt_f="11229">).</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="16401" xml_f="16408" txt_i="11230" txt_f="11237">Table 1</offsets></label><caption><p><offsets xml_i="16428" xml_f="16479" txt_i="11237" txt_f="11288">Subject characteristics at baseline (safety sample)</offsets></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="top"><tr><th rowspan="3" align="left"><offsets xml_i="16717" xml_f="16718" txt_i="11289" txt_f="11290"> </offsets></th><th align="center" valign="bottom"><bold><offsets xml_i="16764" xml_f="16771" txt_i="11290" txt_f="11297">Group A</offsets></bold><hr></hr></th><th align="center" valign="bottom"><bold><offsets xml_i="16833" xml_f="16840" txt_i="11297" txt_f="11304">Group B</offsets></bold><hr></hr></th><th rowspan="3" align="center" valign="top"><bold><italic><offsets xml_i="16919" xml_f="16920" txt_i="11304" txt_f="11305">p</offsets></italic></bold></th></tr><tr><th align="center" valign="bottom"><bold><offsets xml_i="16991" xml_f="16999" txt_i="11305" txt_f="11313">(N = 30)</offsets></bold><hr></hr></th><th align="center" valign="bottom"><bold><offsets xml_i="17061" xml_f="17069" txt_i="11313" txt_f="11321">(N = 25)</offsets></bold><hr></hr></th></tr><tr><th align="center"><bold><offsets xml_i="17124" xml_f="17133" txt_i="11321" txt_f="11330">Mean ± SD</offsets></bold></th><th align="center"><bold><offsets xml_i="17170" xml_f="17179" txt_i="11330" txt_f="11339">Mean ± SD</offsets></bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><offsets xml_i="17261" xml_f="17272" txt_i="11339" txt_f="11350">AGE (years)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="17321" xml_f="17331" txt_i="11351" txt_f="11361">73.2 ± 8.7</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="17380" xml_f="17390" txt_i="11362" txt_f="11372">73.9 ± 7.7</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="17439" xml_f="17441" txt_i="11373" txt_f="11375">NS</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="17497" xml_f="17506" txt_i="11376" txt_f="11385">BMI (Kg/m</offsets><sup><offsets xml_i="17511" xml_f="17512" txt_i="11385" txt_f="11386">2</offsets></sup><offsets xml_i="17518" xml_f="17519" txt_i="11386" txt_f="11387">)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="17568" xml_f="17578" txt_i="11388" txt_f="11398">30.8 ± 8.8</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="17627" xml_f="17637" txt_i="11399" txt_f="11409">29.3 ± 7.9</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="17686" xml_f="17688" txt_i="11410" txt_f="11412">NS</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="17744" xml_f="17747" txt_i="11413" txt_f="11416">PaO</offsets><sub><offsets xml_i="17752" xml_f="17753" txt_i="11416" txt_f="11417">2</offsets></sub><offsets xml_i="17759" xml_f="17766" txt_i="11417" txt_f="11424"> (mmHg)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="17815" xml_f="17825" txt_i="11425" txt_f="11435">58.2 ± 4.9</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="17874" xml_f="17884" txt_i="11436" txt_f="11446">58.2 ± 6.4</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="17933" xml_f="17935" txt_i="11447" txt_f="11449">NS</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="17991" xml_f="17995" txt_i="11450" txt_f="11454">PaCO</offsets><sub><offsets xml_i="18000" xml_f="18001" txt_i="11454" txt_f="11455">2</offsets></sub><offsets xml_i="18007" xml_f="18014" txt_i="11455" txt_f="11462"> (mmHg)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18063" xml_f="18073" txt_i="11463" txt_f="11473">45.0 ± 4.4</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18122" xml_f="18132" txt_i="11474" txt_f="11484">43.9 ± 5.4</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18181" xml_f="18183" txt_i="11485" txt_f="11487">NS</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="18239" xml_f="18242" txt_i="11488" txt_f="11491">FEV</offsets><sub><offsets xml_i="18247" xml_f="18248" txt_i="11491" txt_f="11492">1</offsets></sub><offsets xml_i="18254" xml_f="18264" txt_i="11492" txt_f="11502"> (% pred.)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18313" xml_f="18324" txt_i="11503" txt_f="11514">41.7 ± 14.6</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18373" xml_f="18384" txt_i="11515" txt_f="11526">44.0 ± 14.6</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18433" xml_f="18435" txt_i="11527" txt_f="11529">NS</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="18491" xml_f="18503" txt_i="11530" txt_f="11542">VC (% pred.)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18552" xml_f="18563" txt_i="11543" txt_f="11554">70.0 ± 22.9</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18612" xml_f="18623" txt_i="11555" txt_f="11566">71.3 ± 25.5</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18672" xml_f="18674" txt_i="11567" txt_f="11569">NS</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="18730" xml_f="18742" txt_i="11570" txt_f="11582">RV (% pred.)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18791" xml_f="18803" txt_i="11583" txt_f="11595">116.0 ± 48.7</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18852" xml_f="18864" txt_i="11596" txt_f="11608">115.8 ± 51.5</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18913" xml_f="18915" txt_i="11609" txt_f="11611">NS</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="18971" xml_f="18973" txt_i="11612" txt_f="11614">DL</offsets><sub><offsets xml_i="18978" xml_f="18980" txt_i="11614" txt_f="11616">CO</offsets></sub><offsets xml_i="18986" xml_f="18996" txt_i="11616" txt_f="11626"> (% pred.)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="19045" xml_f="19056" txt_i="11627" txt_f="11638">58.1 ± 23.6</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="19105" xml_f="19116" txt_i="11639" txt_f="11650">61.7 ± 33.5</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="19165" xml_f="19167" txt_i="11651" txt_f="11653">NS</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="19223" xml_f="19226" txt_i="11654" txt_f="11657">MRC</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="19275" xml_f="19286" txt_i="11658" txt_f="11669">4.96 ± 0.73</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="19335" xml_f="19346" txt_i="11670" txt_f="11681">4.04 ± 0.76</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="19395" xml_f="19397" txt_i="11682" txt_f="11684">NS</offsets><hr></hr></td></tr><tr><td align="left"><offsets xml_i="19437" xml_f="19450" txt_i="11685" txt_f="11698">6MWT (meters)</offsets></td><td align="center"><offsets xml_i="19474" xml_f="19486" txt_i="11699" txt_f="11711">236.4 ± 91.4</offsets></td><td align="center"><offsets xml_i="19510" xml_f="19522" txt_i="11712" txt_f="11724">249.3 ± 74.2</offsets></td><td align="center"><offsets xml_i="19546" xml_f="19548" txt_i="11725" txt_f="11727">NS</offsets></td></tr></tbody></table><table-wrap-foot><p><italic><offsets xml_i="19602" xml_f="19604" txt_i="11728" txt_f="11730">NS</offsets></italic><offsets xml_i="19613" xml_f="19651" txt_i="11730" txt_f="11768"> Not Significant; Independent-Samples </offsets><italic><offsets xml_i="19659" xml_f="19660" txt_i="11768" txt_f="11769">t</offsets></italic><offsets xml_i="19669" xml_f="19675" txt_i="11769" txt_f="11775">-Test.</offsets></p></table-wrap-foot></table-wrap><p><offsets xml_i="19713" xml_f="19943" txt_i="11776" txt_f="12006">Patients characteristics showed COPD patients with chronic respiratory failure, advanced age, overweight with fat-free mass preserved, moderate impairment of lung diffusion, high degree of dyspnea and decreased exercise tolerance.</offsets></p><sec><title><offsets xml_i="19959" xml_f="19998" txt_i="12007" txt_f="12046">Body composition and exercise tolerance</offsets></title><p><offsets xml_i="20009" xml_f="20104" txt_i="12047" txt_f="12142">From baseline to the end of the double-blind period (T1, two months of therapy), the FFMI (Kg/m</offsets><sup><offsets xml_i="20109" xml_f="20110" txt_i="12142" txt_f="12143">2</offsets></sup><offsets xml_i="20116" xml_f="20279" txt_i="12143" txt_f="12306">) increased in the daily dietary supplementation group (+ 3.7) and decreased in the placebo group (- 0.6 ), resulting in a statistically significant (ANCOVA model </offsets><italic><offsets xml_i="20287" xml_f="20288" txt_i="12306" txt_f="12307">p</offsets></italic><offsets xml_i="20297" xml_f="20480" txt_i="12307" txt_f="12487"> &lt; 0.001) treatment difference. Statistically significant treatment differences, favouring daily dietary supplementation group, were also seen for the 6MWT (mtr) comparison (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="20512" xml_f="20513" txt_i="12487" txt_f="12488">2</offsets></xref><offsets xml_i="20520" xml_f="20522" txt_i="12488" txt_f="12490">).</offsets></p><table-wrap position="float" id="T2"><label><offsets xml_i="20570" xml_f="20577" txt_i="12491" txt_f="12498">Table 2</offsets></label><caption><p><bold><offsets xml_i="20603" xml_f="20694" txt_i="12498" txt_f="12589">Comparison of the free fat mass index (FFMI) and 6MWT distance within-group (Paired sample </offsets></bold><bold><italic><offsets xml_i="20715" xml_f="20716" txt_i="12589" txt_f="12590">t</offsets></italic></bold><bold><offsets xml_i="20738" xml_f="20835" txt_i="12590" txt_f="12687">-Test, T0 vs T1) and between-groups (ANCOVA with baseline value as covariate, Group A vs Group B)</offsets></bold></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="top"><tr><th rowspan="3" align="left"><offsets xml_i="21158" xml_f="21159" txt_i="12688" txt_f="12689"> </offsets></th><th colspan="3" align="center" valign="bottom"><bold><offsets xml_i="21217" xml_f="21227" txt_i="12689" txt_f="12699">FFMI (Kg/m</offsets></bold><sup><bold><offsets xml_i="21245" xml_f="21246" txt_i="12699" txt_f="12700">2</offsets></bold></sup><bold><offsets xml_i="21265" xml_f="21266" txt_i="12700" txt_f="12701">)</offsets></bold><hr></hr></th><th colspan="3" align="center" valign="bottom"><bold><offsets xml_i="21340" xml_f="21350" txt_i="12701" txt_f="12711">6MWT (mtr)</offsets></bold><hr></hr></th></tr><tr><th align="center" valign="bottom"><bold><offsets xml_i="21421" xml_f="21423" txt_i="12711" txt_f="12713">T0</offsets></bold><hr></hr></th><th align="center" valign="bottom"><bold><offsets xml_i="21485" xml_f="21487" txt_i="12713" txt_f="12715">T1</offsets></bold><hr></hr></th><th align="center" valign="bottom"><bold><offsets xml_i="21549" xml_f="21561" txt_i="12715" txt_f="12727">Within-group</offsets></bold><hr></hr></th><th align="center" valign="bottom"><bold><offsets xml_i="21623" xml_f="21625" txt_i="12727" txt_f="12729">T0</offsets></bold><hr></hr></th><th align="center" valign="bottom"><bold><offsets xml_i="21687" xml_f="21689" txt_i="12729" txt_f="12731">T1</offsets></bold><hr></hr></th><th align="center" valign="bottom"><bold><offsets xml_i="21751" xml_f="21763" txt_i="12731" txt_f="12743">Within-group</offsets></bold><hr></hr></th></tr><tr><th align="center"><bold><offsets xml_i="21818" xml_f="21827" txt_i="12743" txt_f="12752">Mean ± SD</offsets></bold></th><th align="center"><bold><offsets xml_i="21864" xml_f="21873" txt_i="12752" txt_f="12761">Mean ± SD</offsets></bold></th><th align="center"><bold><italic><offsets xml_i="21918" xml_f="21919" txt_i="12761" txt_f="12762">p</offsets></italic></bold></th><th align="center"><bold><offsets xml_i="21965" xml_f="21974" txt_i="12762" txt_f="12771">Mean ± SD</offsets></bold></th><th align="center"><bold><offsets xml_i="22011" xml_f="22020" txt_i="12771" txt_f="12780">Mean ± SD</offsets></bold></th><th align="center"><bold><italic><offsets xml_i="22065" xml_f="22066" txt_i="12780" txt_f="12781">p</offsets></italic></bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold><offsets xml_i="22163" xml_f="22170" txt_i="12781" txt_f="12788">Group A</offsets></bold><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="22226" xml_f="22236" txt_i="12789" txt_f="12799">17.1 ± 6.5</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="22285" xml_f="22295" txt_i="12800" txt_f="12810">20.8 ± 7.4</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="22344" xml_f="22354" txt_i="12811" txt_f="12818">&lt; 0.001</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="22403" xml_f="22415" txt_i="12819" txt_f="12831">236.4 ± 91.4</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="22464" xml_f="22476" txt_i="12832" txt_f="12844">303.7 ± 88.1</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="22525" xml_f="22535" txt_i="12845" txt_f="12852">&lt; 0.001</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><bold><offsets xml_i="22597" xml_f="22604" txt_i="12853" txt_f="12860">Group B</offsets></bold><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="22660" xml_f="22670" txt_i="12861" txt_f="12871">19.3 ± 5.5</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="22719" xml_f="22729" txt_i="12872" txt_f="12882">18.7 ± 4.3</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="22778" xml_f="22783" txt_i="12883" txt_f="12888">0.093</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="22832" xml_f="22844" txt_i="12889" txt_f="12901">249.3 ± 74.2</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="22893" xml_f="22905" txt_i="12902" txt_f="12914">203.9 ± 88.1</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="22954" xml_f="22959" txt_i="12915" txt_f="12920">0.021</offsets><hr></hr></td></tr><tr><td align="left"><bold><offsets xml_i="23005" xml_f="23012" txt_i="12921" txt_f="12928">Between</offsets></bold><offsets xml_i="23019" xml_f="23035" txt_i="12928" txt_f="12944">- groups ANCOVA </offsets><italic><offsets xml_i="23043" xml_f="23044" txt_i="12944" txt_f="12945">p</offsets></italic></td><td align="center"><offsets xml_i="23077" xml_f="23078" txt_i="12946" txt_f="12947">-</offsets></td><td align="center"><offsets xml_i="23102" xml_f="23112" txt_i="12948" txt_f="12955">&lt; 0.001</offsets></td><td align="center"><offsets xml_i="23136" xml_f="23137" txt_i="12956" txt_f="12957">-</offsets></td><td align="center"><offsets xml_i="23161" xml_f="23162" txt_i="12958" txt_f="12959">-</offsets></td><td align="center"><offsets xml_i="23186" xml_f="23196" txt_i="12960" txt_f="12967">&lt; 0.001</offsets></td><td align="center"><offsets xml_i="23220" xml_f="23221" txt_i="12968" txt_f="12969">-</offsets></td></tr></tbody></table></table-wrap><p><offsets xml_i="23263" xml_f="23592" txt_i="12970" txt_f="13299">During the treatment period the FFMI increased, with consequent BMI increase, only in patients treated with dietary supplementation (group A), in comparison to patients treated with placebo (group B). After two months of treatment the FFMI and BMI comparisons between groups showed a statistically significant difference (Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="23622" xml_f="23623" txt_i="13299" txt_f="13300">1</offsets></xref><offsets xml_i="23630" xml_f="23632" txt_i="13300" txt_f="13302">).</offsets></p><fig id="F1" position="float"><label><offsets xml_i="23673" xml_f="23681" txt_i="13303" txt_f="13311">Figure 1</offsets></label><caption><p><bold><offsets xml_i="23707" xml_f="23814" txt_i="13311" txt_f="13418">End of study comparison between the two groups of the Fat Free Mass Index (FFMI) and Body Mass Index (BMI).</offsets></bold><offsets xml_i="23821" xml_f="23856" txt_i="13418" txt_f="13453"> After two months of therapy FFMI (</offsets><italic><offsets xml_i="23864" xml_f="23865" txt_i="13453" txt_f="13454">p</offsets></italic><offsets xml_i="23874" xml_f="23896" txt_i="13454" txt_f="13473"> &lt; 0.001) and BMI (</offsets><italic><offsets xml_i="23904" xml_f="23905" txt_i="13473" txt_f="13474">p</offsets></italic><offsets xml_i="23914" xml_f="23997" txt_i="13474" txt_f="13554"> &lt; 0.01) were higher in patients treated with dietary supplementation (group A).</offsets></p></caption><graphic xlink:href="2049-6958-8-40-1"></graphic></fig></sec><sec><title><offsets xml_i="24084" xml_f="24091" txt_i="13556" txt_f="13563">Dyspnea</offsets></title><p><offsets xml_i="24102" xml_f="24274" txt_i="13564" txt_f="13736">The evaluation of dyspnea degree using different scales (Borg, VAS, MRC, BDI) showed a significant improvement of dyspnea in Group A at T1 (VAS: 3.81 ± 2.12 vs 2.94 ± 2.34 </offsets><italic><offsets xml_i="24282" xml_f="24283" txt_i="13736" txt_f="13737">p</offsets></italic><offsets xml_i="24292" xml_f="24338" txt_i="13737" txt_f="13780"> &lt; 0.05; Borg: 2.96 ± 1.59 vs 2.31 ± 1.67, </offsets><italic><offsets xml_i="24346" xml_f="24347" txt_i="13780" txt_f="13781">p</offsets></italic><offsets xml_i="24356" xml_f="24401" txt_i="13781" txt_f="13823"> &lt; 0.05; MRC: 3, 96 ± 0.73 vs 3.0 ± 1.06, </offsets><italic><offsets xml_i="24409" xml_f="24410" txt_i="13823" txt_f="13824">p</offsets></italic><offsets xml_i="24419" xml_f="24466" txt_i="13824" txt_f="13868"> &lt; 0.000; BDI1: 1.65 ± 1.11 vs 2.37 ± 0.82, </offsets><italic><offsets xml_i="24474" xml_f="24475" txt_i="13868" txt_f="13869">p</offsets></italic><offsets xml_i="24484" xml_f="24531" txt_i="13869" txt_f="13913"> &lt; 0.05; BDI3: 1.82 ± 1. 03 vs 2.48 ± 0.73, </offsets><italic><offsets xml_i="24539" xml_f="24540" txt_i="13913" txt_f="13914">p</offsets></italic><offsets xml_i="24549" xml_f="24681" txt_i="13914" txt_f="14043"> &lt; 0.03). BDI2 scale showed no significant differences in group A, while all dyspnea evaluations in group B were not significant.</offsets></p><p><offsets xml_i="24688" xml_f="24879" txt_i="14044" txt_f="14235">A higher rate of group A patients showed improved or stable dyspnea values (26.1% vs 65.6% BORG; VAS: 68,9% vs 34.8%; MRC: 69% vs 56.5%; BDI1: 58.7% vs. 21.7%; BDI3: 62.1% vs. 11.1%) (Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="24909" xml_f="24910" txt_i="14235" txt_f="14236">2</offsets></xref><offsets xml_i="24917" xml_f="24919" txt_i="14236" txt_f="14238">).</offsets></p><fig id="F2" position="float"><label><offsets xml_i="24960" xml_f="24968" txt_i="14239" txt_f="14247">Figure 2</offsets></label><caption><p><bold><offsets xml_i="24994" xml_f="25168" txt_i="14247" txt_f="14421">Comparison (T0 vs T1) between rate of patients of two groups with improvement, stabilization and worsening dyspnea (Borg, VAS, MRC and BDI scale), before and after treatment.</offsets></bold><offsets xml_i="25175" xml_f="25242" txt_i="14421" txt_f="14488"> Significant higher rate of stable or improved patients in group A.</offsets></p></caption><graphic xlink:href="2049-6958-8-40-2"></graphic></fig></sec><sec><title><offsets xml_i="25329" xml_f="25359" txt_i="14490" txt_f="14520">Functional independence degree</offsets></title><p><offsets xml_i="25370" xml_f="25586" txt_i="14521" txt_f="14737">The evaluation of performance index with Activities of Daily Living scale (ADL) showed a significant improvement in the independence level in activities of daily living in group A at T1 (0.79 ± 1.23 vs. 0.24 ± 0.51, </offsets><italic><offsets xml_i="25594" xml_f="25595" txt_i="14737" txt_f="14738">p</offsets></italic><offsets xml_i="25604" xml_f="25672" txt_i="14738" txt_f="14803"> &lt; 0.03). No significant difference was found in group B (Figure </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="25702" xml_f="25703" txt_i="14803" txt_f="14804">3</offsets></xref><offsets xml_i="25710" xml_f="25712" txt_i="14804" txt_f="14806">).</offsets></p><fig id="F3" position="float"><label><offsets xml_i="25753" xml_f="25761" txt_i="14807" txt_f="14815">Figure 3</offsets></label><caption><p><bold><offsets xml_i="25787" xml_f="25895" txt_i="14815" txt_f="14923">Comparison (T0 vs T1) between Functional Independence Level (Activities of Daily Living- ADL) of two groups.</offsets></bold><offsets xml_i="25902" xml_f="26048" txt_i="14923" txt_f="15069"> Significant improvement in the independence level in activities of daily living in group A at T1. No significant difference was found in group B.</offsets></p></caption><graphic xlink:href="2049-6958-8-40-3"></graphic></fig></sec><sec><title><offsets xml_i="26135" xml_f="26150" txt_i="15071" txt_f="15086">Quality of life</offsets></title><p><offsets xml_i="26161" xml_f="26304" txt_i="15087" txt_f="15227">Quality of life evaluation with the SGRQ at T0 and T1 showed a significant improvement in quality of life (cut-off improvement &gt; 4 points) [</offsets><xref ref-type="bibr" rid="B43"><offsets xml_i="26336" xml_f="26338" txt_i="15227" txt_f="15229">43</offsets></xref><offsets xml_i="26345" xml_f="26467" txt_i="15229" txt_f="15351">] in group A in activities section (- 6, 63 pt) and total score (- 5.43 points). No significant change in group B (Figure </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="26497" xml_f="26498" txt_i="15351" txt_f="15352">4</offsets></xref><offsets xml_i="26505" xml_f="26507" txt_i="15352" txt_f="15354">).</offsets></p><fig id="F4" position="float"><label><offsets xml_i="26548" xml_f="26556" txt_i="15355" txt_f="15363">Figure 4</offsets></label><caption><p><bold><offsets xml_i="26582" xml_f="26663" txt_i="15363" txt_f="15444">Comparison (T0 vs T1) between Quality of Life questionnaire (SGRQ) in two groups.</offsets></bold><offsets xml_i="26670" xml_f="26863" txt_i="15444" txt_f="15634"> A significant improvement in quality of life (cut-off improvement &gt; 4 points) in group A in activities section (- 6.63 pt) and total score (- 5.43 points). No significant change in group B.</offsets></p></caption><graphic xlink:href="2049-6958-8-40-4"></graphic></fig></sec><sec><title><offsets xml_i="26950" xml_f="26963" txt_i="15636" txt_f="15649">Exacerbations</offsets></title><p><offsets xml_i="26974" xml_f="27108" txt_i="15650" txt_f="15784">The exacerbations rate in the year following the start of therapy was significantly decreased in group A (0.51 ± 0.78 vs 0.13 ± 0.35, </offsets><italic><offsets xml_i="27116" xml_f="27117" txt_i="15784" txt_f="15785">p</offsets></italic><offsets xml_i="27126" xml_f="27317" txt_i="15785" txt_f="15973"> &lt; 0.02), with a reduction of 74.6%, compared to baseline. In the placebo group (Group B) no statistically significant difference (0.65 ± 1.11 vs 0.60 ± 0.72, NS) was demonstrated (Figure </offsets><xref ref-type="fig" rid="F5"><offsets xml_i="27347" xml_f="27348" txt_i="15973" txt_f="15974">5</offsets></xref><offsets xml_i="27355" xml_f="27357" txt_i="15974" txt_f="15976">).</offsets></p><fig id="F5" position="float"><label><offsets xml_i="27398" xml_f="27406" txt_i="15977" txt_f="15985">Figure 5</offsets></label><caption><p><bold><offsets xml_i="27432" xml_f="27584" txt_i="15985" txt_f="16137">Comparison between exacerbations rate before (1 year before treatment) and during the study (1 year following the start of treatment) in the two groups.</offsets></bold><offsets xml_i="27591" xml_f="27642" txt_i="16137" txt_f="16188"> Significant reduction of exacerbations in group A.</offsets></p></caption><graphic xlink:href="2049-6958-8-40-5"></graphic></fig></sec></sec><sec sec-type="discussion"><title><offsets xml_i="27757" xml_f="27767" txt_i="16191" txt_f="16201">Discussion</offsets></title><p><offsets xml_i="27778" xml_f="28343" txt_i="16202" txt_f="16767">The results of this study demonstrate that in severe stable COPD patients with chronic respiratory failure, independently of body mass alterations (evident body weight and/or lean body mass reduction), dietary supplementation with a Creatine-Q-Ter compound determines a variation of body mass with lean body mass increase. This change is associated with improvement in exercise capacity and dyspnea, and reduction of exacerbations rate. In these patients such effect leads to a functional independence in the activities of daily living and quality of life increase.</offsets></p><sec><title><offsets xml_i="28359" xml_f="28380" txt_i="16768" txt_f="16789">Malnutrition and COPD</offsets></title><p><offsets xml_i="28391" xml_f="28424" txt_i="16790" txt_f="16823">It has been widely demonstrated [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="28455" xml_f="28456" txt_i="16823" txt_f="16824">9</offsets></xref><offsets xml_i="28463" xml_f="28464" txt_i="16824" txt_f="16825">-</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="28496" xml_f="28498" txt_i="16825" txt_f="16827">20</offsets></xref><offsets xml_i="28505" xml_f="28779" txt_i="16827" txt_f="17101">] that the protein-calorie malnutrition and the underweight status are a constant manifestation of some patients with severe COPD, and it is clear that their cause is the imbalance among inadequate caloric intake, energy expenditure increase and protein turnover alteration.</offsets></p><p><offsets xml_i="28786" xml_f="29045" txt_i="17102" txt_f="17361">The determinants of imbalance are numerous. On the one hand dyspnea influences nutrition through an after-meal diaphragm movement restriction, as well as altered appetite sensation, caused by leptin levels reduction, that is related to systemic inflammation [</offsets><xref ref-type="bibr" rid="B45"><offsets xml_i="29077" xml_f="29079" txt_i="17361" txt_f="17363">45</offsets></xref><offsets xml_i="29086" xml_f="29685" txt_i="17363" txt_f="17962">] and can contribute to a reduced caloric intake. On the other hand, the energy expenditure increase is supported by metabolism increase at rest and after exercise, alteration of the sympathetic regulation and drugs influence. Moreover, systemic inflammation, as demonstrated by the increase in cytokines , such as TNF-alpha, plays a key role in protein turnover. In this regard, an increased apoptosis, that contributed to the exercise limitation, not explained by other causes such as hypoxemia, tobacco smoking and steroid therapy, was detected in the muscle cells of malnourished COPD patients [</offsets><xref ref-type="bibr" rid="B46"><offsets xml_i="29717" xml_f="29719" txt_i="17962" txt_f="17964">46</offsets></xref><offsets xml_i="29726" xml_f="29728" txt_i="17964" txt_f="17966">].</offsets></p><p><offsets xml_i="29735" xml_f="29935" txt_i="17967" txt_f="18167">Finally, oxidative stress, caused in particular by cigarette smoke and neutrophils during exacerbations, is together with chronic inflammation, a principal pathogenetic mechanism for COPD development.</offsets></p></sec><sec><title><offsets xml_i="29957" xml_f="29992" txt_i="18169" txt_f="18204">Muscle and mitochondrial alteration</offsets></title><p><offsets xml_i="30003" xml_f="30258" txt_i="18205" txt_f="18460">Other mechanisms, which are closely related to protein-calorie malnutrition, concerning structural and biochemical alterations of the peripheral muscles, have been demonstrated in COPD patients who also showed muscular fibers and mitochondria alterations.</offsets></p><p><offsets xml_i="30265" xml_f="30510" txt_i="18461" txt_f="18706">There have been several experimental demonstrations of decreased muscle mass in patients with COPD, even in the relatively early stages of the disease, which was reflected in a subsequent reduction of respiratory and peripheral muscle strength [</offsets><xref ref-type="bibr" rid="B47"><offsets xml_i="30542" xml_f="30544" txt_i="18706" txt_f="18708">47</offsets></xref><offsets xml_i="30551" xml_f="30553" txt_i="18708" txt_f="18710">].</offsets></p><p><offsets xml_i="30560" xml_f="30833" txt_i="18711" txt_f="18984">Moreover, studies on muscle biopsies clarify that in the muscles of these patients there is a qualitative adaptation mechanism, like a greater presence of type II muscle fibers, able to easily use an anaerobic metabolism, compared to type I fibers with aerobic metabolism [</offsets><xref ref-type="bibr" rid="B48"><offsets xml_i="30865" xml_f="30867" txt_i="18984" txt_f="18986">48</offsets></xref><offsets xml_i="30874" xml_f="31074" txt_i="18986" txt_f="19186">]. This change reflects a reduced aerobic capacity of the muscle of COPD patients, especially if hypoxemic, with a greater use of renewable anaerobic energy and reduced peripheral oxygen consumption [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="31106" xml_f="31108" txt_i="19186" txt_f="19188">21</offsets></xref><offsets xml_i="31115" xml_f="31116" txt_i="19188" txt_f="19189">,</offsets><xref ref-type="bibr" rid="B49"><offsets xml_i="31148" xml_f="31150" txt_i="19189" txt_f="19191">49</offsets></xref><offsets xml_i="31157" xml_f="31159" txt_i="19191" txt_f="19193">].</offsets></p><p><offsets xml_i="31166" xml_f="31291" txt_i="19194" txt_f="19319">Interesting results were achieved by investigations about muscular changes related to muscle mitochondrial energy production.</offsets></p><p><offsets xml_i="31298" xml_f="31388" txt_i="19320" txt_f="19410">Muscle mitochondrial alterations have been demonstrated both in terms of reduced density [</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="31420" xml_f="31422" txt_i="19410" txt_f="19412">31</offsets></xref><offsets xml_i="31429" xml_f="31464" txt_i="19412" txt_f="19447">] and in function of cytochrome C [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="31496" xml_f="31498" txt_i="19447" txt_f="19449">28</offsets></xref><offsets xml_i="31505" xml_f="31507" txt_i="19449" txt_f="19451">].</offsets></p><p><offsets xml_i="31514" xml_f="31752" txt_i="19452" txt_f="19690">Studies performed in underweight and normal weight COPD patients (muscle biopsies) showed a reduction of mitochondrial function in underweight patients caused by abnormal electron transport and consequent worsening of muscular endurance [</offsets><xref ref-type="bibr" rid="B50"><offsets xml_i="31784" xml_f="31786" txt_i="19690" txt_f="19692">50</offsets></xref><offsets xml_i="31793" xml_f="31870" txt_i="19692" txt_f="19769">]. Puente-Maestu et al. confirmed this phenomenon in COPD muscular biopsies [</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="31902" xml_f="31904" txt_i="19769" txt_f="19771">29</offsets></xref><offsets xml_i="31911" xml_f="32129" txt_i="19771" txt_f="19989">], also at the early stage of disease, with an altered mithocondrial electron transport and an increase in ROS, that is a possible cause of systemic oxidative muscular damage. On the other hand, the studies of Ribera [</offsets><xref ref-type="bibr" rid="B51"><offsets xml_i="32161" xml_f="32163" txt_i="19989" txt_f="19991">51</offsets></xref><offsets xml_i="32170" xml_f="32182" txt_i="19991" txt_f="20003">], Hamaoka [</offsets><xref ref-type="bibr" rid="B52"><offsets xml_i="32214" xml_f="32216" txt_i="20003" txt_f="20005">52</offsets></xref><offsets xml_i="32223" xml_f="32233" txt_i="20005" txt_f="20015">], Layec [</offsets><xref ref-type="bibr" rid="B53"><offsets xml_i="32265" xml_f="32267" txt_i="20015" txt_f="20017">53</offsets></xref><offsets xml_i="32274" xml_f="32288" txt_i="20017" txt_f="20031">] and Picard [</offsets><xref ref-type="bibr" rid="B54"><offsets xml_i="32320" xml_f="32322" txt_i="20031" txt_f="20033">54</offsets></xref><offsets xml_i="32329" xml_f="32500" txt_i="20033" txt_f="20204">] come to a different conclusion: in fact, while confirming the reduced muscular efficiency, they did not show alterations of mitochondrial function and energy production.</offsets></p></sec><sec><title><offsets xml_i="32522" xml_f="32567" txt_i="20206" txt_f="20251">Effects of changes in dietary supplementation</offsets></title><p><offsets xml_i="32578" xml_f="32694" txt_i="20252" txt_f="20368">Attempts to significantly influence body composition through a diet variation, with increase both in carbohydrates [</offsets><xref ref-type="bibr" rid="B55"><offsets xml_i="32726" xml_f="32728" txt_i="20368" txt_f="20370">55</offsets></xref><offsets xml_i="32735" xml_f="32752" txt_i="20370" txt_f="20387">] and in lipids [</offsets><xref ref-type="bibr" rid="B56"><offsets xml_i="32784" xml_f="32786" txt_i="20387" txt_f="20389">56</offsets></xref><offsets xml_i="32793" xml_f="32892" txt_i="20389" txt_f="20488">], have obtained controversial results, also in COPD patients undergoing rehabilitation treatment [</offsets><xref ref-type="bibr" rid="B57"><offsets xml_i="32924" xml_f="32926" txt_i="20488" txt_f="20490">57</offsets></xref><offsets xml_i="32933" xml_f="32935" txt_i="20490" txt_f="20492">].</offsets></p><p><offsets xml_i="32942" xml_f="33260" txt_i="20493" txt_f="20811">In particular, in a study by Steinert et al., carbohydrate supplementation has been shown to improve exercise capacity in underweight COPD patients compared to control, despite a body weight increase, while normal-weight COPD patients achieved an improved exercise capacity related to the supplement of carbohydrates [</offsets><xref ref-type="bibr" rid="B58"><offsets xml_i="33292" xml_f="33294" txt_i="20811" txt_f="20813">58</offsets></xref><offsets xml_i="33301" xml_f="33316" txt_i="20813" txt_f="20828">]. Cai et al. [</offsets><xref ref-type="bibr" rid="B56"><offsets xml_i="33348" xml_f="33350" txt_i="20828" txt_f="20830">56</offsets></xref><offsets xml_i="33357" xml_f="33447" txt_i="20830" txt_f="20920">], inversely, in about 60 malnourished COPD patients showed that respiratory function (FEV</offsets><sub><offsets xml_i="33452" xml_f="33453" txt_i="20920" txt_f="20921">1</offsets></sub><offsets xml_i="33459" xml_f="33665" txt_i="20921" txt_f="21127"> and ventilation/min), blood gases and respiratory quotient significantly improved after a 3 week of high lipid- low carbohydrate supplementation diet , compared with a traditional diet (high carbohydrate).</offsets></p><p><offsets xml_i="33672" xml_f="33705" txt_i="21128" txt_f="21161">Recently, the Engelen’s studies [</offsets><xref ref-type="bibr" rid="B59"><offsets xml_i="33737" xml_f="33739" txt_i="21161" txt_f="21163">59</offsets></xref><offsets xml_i="33746" xml_f="33747" txt_i="21163" txt_f="21164">,</offsets><xref ref-type="bibr" rid="B60"><offsets xml_i="33779" xml_f="33781" txt_i="21164" txt_f="21166">60</offsets></xref><offsets xml_i="33788" xml_f="34064" txt_i="21166" txt_f="21442">] achieved some interesting conclusions, demonstrating an increased anabolic response to milk proteins, in particular casein (oral and intravenous) associated with reduced splanchnic extraction of essential amino acids in normal-weight COPD patients during and after exercise.</offsets></p></sec><sec><title><offsets xml_i="34086" xml_f="34117" txt_i="21444" txt_f="21475">Effects of a dietary supplement</offsets></title><p><offsets xml_i="34128" xml_f="34209" txt_i="21476" txt_f="21557">Interesting results have been observed with the aminoacids diet supplementation [</offsets><xref ref-type="bibr" rid="B61"><offsets xml_i="34241" xml_f="34243" txt_i="21557" txt_f="21559">61</offsets></xref><offsets xml_i="34250" xml_f="34251" txt_i="21559" txt_f="21560">,</offsets><xref ref-type="bibr" rid="B62"><offsets xml_i="34283" xml_f="34285" txt_i="21560" txt_f="21562">62</offsets></xref><offsets xml_i="34292" xml_f="34399" txt_i="21562" txt_f="21669">]. Essential aminoacids in fact promote and enhance protein synthesis and increase muscular tissue growth [</offsets><xref ref-type="bibr" rid="B63"><offsets xml_i="34431" xml_f="34433" txt_i="21669" txt_f="21671">63</offsets></xref><offsets xml_i="34440" xml_f="34442" txt_i="21671" txt_f="21673">].</offsets></p><p><offsets xml_i="34449" xml_f="34658" txt_i="21674" txt_f="21883">Sarcopenic COPD patients who underwent rehabilitation program and 12 weeks essential aminoacid supplementation, increased muscle mass, muscle strength, physical activity, cognitive status and quality of life [</offsets><xref ref-type="bibr" rid="B61"><offsets xml_i="34690" xml_f="34692" txt_i="21883" txt_f="21885">61</offsets></xref><offsets xml_i="34699" xml_f="34700" txt_i="21885" txt_f="21886">,</offsets><xref ref-type="bibr" rid="B62"><offsets xml_i="34732" xml_f="34734" txt_i="21886" txt_f="21888">62</offsets></xref><offsets xml_i="34741" xml_f="34809" txt_i="21888" txt_f="21956">] and improved muscle metabolism with a lower lactate concentration.</offsets></p><p><offsets xml_i="34816" xml_f="35186" txt_i="21957" txt_f="22327">Other clinical trials, conducted in healthy subjects showed that creatine diet supplementation can increase lean body mass and physical performance through increased deposition of phosphocreatine (phosphorylated form of creatine) in muscle and brain, that reduces the loss of ATP, stimulates protein synthesis, reduces protein catabolism, and stabilizes cell membranes [</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="35218" xml_f="35220" txt_i="22327" txt_f="22329">37</offsets></xref><offsets xml_i="35227" xml_f="35383" txt_i="22329" txt_f="22485">]. Studies in patients with chronic heart failure (CHF), in whom phosphocreatine / ATP ratio is a stronger prognostic factor than the degree of impairment [</offsets><xref ref-type="bibr" rid="B64"><offsets xml_i="35415" xml_f="35417" txt_i="22485" txt_f="22487">64</offsets></xref><offsets xml_i="35424" xml_f="35585" txt_i="22487" txt_f="22648">], showed that dietary supplementation with creatine increases creatine phosphate resynthesis and is associated with increased muscular mass strength and power [</offsets><xref ref-type="bibr" rid="B65"><offsets xml_i="35617" xml_f="35619" txt_i="22648" txt_f="22650">65</offsets></xref><offsets xml_i="35626" xml_f="35627" txt_i="22650" txt_f="22651">,</offsets><xref ref-type="bibr" rid="B66"><offsets xml_i="35659" xml_f="35661" txt_i="22651" txt_f="22653">66</offsets></xref><offsets xml_i="35668" xml_f="35670" txt_i="22653" txt_f="22655">].</offsets></p><p><offsets xml_i="35677" xml_f="35708" txt_i="22656" txt_f="22687">On this evidence Fuld’s study [</offsets><xref ref-type="bibr" rid="B40"><offsets xml_i="35740" xml_f="35742" txt_i="22687" txt_f="22689">40</offsets></xref><offsets xml_i="35749" xml_f="35991" txt_i="22689" txt_f="22931">] showed that, in 38 severe COPD patients, selected to receive creatine monohydrate or placebo during pulmonary rehabilitation, creatine diet supplementation increased lean body mass, peripheral muscular strength, endurance and health status.</offsets></p><p><offsets xml_i="35998" xml_f="36124" txt_i="22932" txt_f="23058">Recently several investigators focused on the study of a very important molecule in the muscular energy production: Coenzyme Q</offsets><sub><offsets xml_i="36129" xml_f="36131" txt_i="23058" txt_f="23060">10</offsets></sub><offsets xml_i="36137" xml_f="36511" txt_i="23060" txt_f="23434"> or ubiquinone. It is a powerful antioxidant, synthesized by human cells (mainly concentrated in the myocardium, liver and adrenal gland), which has a key role in the electron transport chain and consequently in the energy synthesis (ATP) at mitochondrial level. It stabilizes also cell membranes, where it acts as a scavenger of ROS. One of the principal limitations of CoQ</offsets><sub><offsets xml_i="36516" xml_f="36518" txt_i="23434" txt_f="23436">10</offsets></sub><offsets xml_i="36524" xml_f="36593" txt_i="23436" txt_f="23505"> clinical use is its reduced oral absorption, currently passed by CoQ</offsets><sub><offsets xml_i="36598" xml_f="36600" txt_i="23505" txt_f="23507">10</offsets></sub><offsets xml_i="36606" xml_f="36651" txt_i="23507" txt_f="23552">-terclatrat to Q-Ter (multicompoundCoenzima Q</offsets><sub><offsets xml_i="36656" xml_f="36658" txt_i="23552" txt_f="23554">10</offsets></sub><offsets xml_i="36664" xml_f="36707" txt_i="23554" txt_f="23597"> based, obtained through mechano-physic CoQ</offsets><sub><offsets xml_i="36712" xml_f="36714" txt_i="23597" txt_f="23599">10</offsets></sub><offsets xml_i="36720" xml_f="36838" txt_i="23599" txt_f="23717"> activation with carrier and bioactivator function materials) 200 times more water-soluble and therefore bioavailable.</offsets></p><p><offsets xml_i="36845" xml_f="36975" txt_i="23718" txt_f="23848">Studies conducted in chronic heart failure patients showed its important role in improving cardiac output and oxygen consumption [</offsets><xref ref-type="bibr" rid="B67"><offsets xml_i="37007" xml_f="37009" txt_i="23848" txt_f="23850">67</offsets></xref><offsets xml_i="37016" xml_f="37017" txt_i="23850" txt_f="23851">,</offsets><xref ref-type="bibr" rid="B68"><offsets xml_i="37049" xml_f="37051" txt_i="23851" txt_f="23853">68</offsets></xref><offsets xml_i="37058" xml_f="37111" txt_i="23853" txt_f="23906">] and also as an independent predictor of mortality [</offsets><xref ref-type="bibr" rid="B69"><offsets xml_i="37143" xml_f="37145" txt_i="23906" txt_f="23908">69</offsets></xref><offsets xml_i="37152" xml_f="37231" txt_i="23908" txt_f="23987">] actually investigated in a multicenter large International study (Q-symbio) [</offsets><xref ref-type="bibr" rid="B70"><offsets xml_i="37263" xml_f="37265" txt_i="23987" txt_f="23989">70</offsets></xref><offsets xml_i="37272" xml_f="37274" txt_i="23989" txt_f="23991">].</offsets></p><p><offsets xml_i="37281" xml_f="37310" txt_i="23992" txt_f="24021">Even COPD patients showed CoQ</offsets><sub><offsets xml_i="37315" xml_f="37317" txt_i="24021" txt_f="24023">10</offsets></sub><offsets xml_i="37323" xml_f="37335" txt_i="24023" txt_f="24035"> reduction [</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="37367" xml_f="37369" txt_i="24035" txt_f="24037">35</offsets></xref><offsets xml_i="37376" xml_f="37465" txt_i="24037" txt_f="24126">] that may contribute to the reduction of muscular efficiency observed in these patients.</offsets></p><p><offsets xml_i="37472" xml_f="37542" txt_i="24127" txt_f="24197">An interesting clinical trial in patients with chronic heart failure [</offsets><xref ref-type="bibr" rid="B71"><offsets xml_i="37574" xml_f="37576" txt_i="24197" txt_f="24199">71</offsets></xref><offsets xml_i="37583" xml_f="37597" txt_i="24199" txt_f="24213">] assuming CoQ</offsets><sub><offsets xml_i="37602" xml_f="37604" txt_i="24213" txt_f="24215">10</offsets></sub><offsets xml_i="37610" xml_f="37781" txt_i="24215" txt_f="24386"> and creatine led to the conclusion that such supplementation improves exercise tolerance and quality of life of patients with severe left ventricular cardiac dysfunction.</offsets></p></sec></sec><sec sec-type="conclusions"><title><offsets xml_i="37832" xml_f="37843" txt_i="24389" txt_f="24400">Conclusions</offsets></title><p><offsets xml_i="37854" xml_f="38162" txt_i="24401" txt_f="24709">This pilot, double-blind, placebo-controlled trial, has been conducted in BPCO patients with chronic respiratory failure and long term oxygen therapy in order to verify the effectiveness of dietary supplementation of creatine and Qter in reducing dyspnea and improving exercise tolerance and quality of life.</offsets></p><p><offsets xml_i="38169" xml_f="38833" txt_i="24710" txt_f="25374">These results show that such supplementation, safe and well tolerated, increases lean body mass level and exercise capacity of these patients, reducing dyspnea. These effects, likely determined by the greater availability of elements, crucial for muscular energy production, allow patients to improve their functional independence with more opportunities to perform activities of daily living and to achieve a better quality of life. Disease stabilization, increased patient functional activity, oxidative load decrease , cause a significantly reduction of disease exacerbations, and consequently of respiratory functional decline and mortality, in these patients.</offsets></p><p><offsets xml_i="38840" xml_f="39105" txt_i="25375" txt_f="25640">This study, of course, has some limits, consequent to a small sample size, lack of data on the elements plasma concentration, and finally a limited prospective time observation. The results of this study, however, provide a demonstration that, in COPD patients in O</offsets><sub><offsets xml_i="39110" xml_f="39111" txt_i="25640" txt_f="25641">2</offsets></sub><offsets xml_i="39117" xml_f="39269" txt_i="25641" txt_f="25793">TLT, nutraceutical supplement acting on protein synthesis and muscular efficiency, can significantly influence the systemic consequences of the disease.</offsets></p><p><offsets xml_i="39276" xml_f="39408" txt_i="25794" txt_f="25926">Further prospective studies with larger population samples are needed to confirm the effectiveness of this nutritional intervention.</offsets></p></sec><sec><title><offsets xml_i="39430" xml_f="39449" txt_i="25928" txt_f="25947">Competing interests</offsets></title><p><offsets xml_i="39460" xml_f="39518" txt_i="25948" txt_f="26006">The authors declare that they have no competing interests.</offsets></p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Schols</surname><given-names>AMWJ</given-names></name><name><surname>Broekhuizen</surname><given-names>R</given-names></name><name><surname>Weling-Sheepers</surname><given-names>CA</given-names></name><name><surname>Wouters</surname><given-names>EF</given-names></name><article-title>Body composition and mortality in chronic obstructive pulmonary disease</article-title><source>Am J Clin Nutr</source><year>2005</year><volume>82</volume><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">16002800</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Marquis</surname><given-names>K</given-names></name><name><surname>Debigaré</surname><given-names>R</given-names></name><name><surname>Lacasse</surname><given-names>Y</given-names></name><name><surname>LeBlanc</surname><given-names>P</given-names></name><name><surname>Jobin</surname><given-names>J</given-names></name><name><surname>Carrier</surname><given-names>G</given-names></name><name><surname>Maltais</surname><given-names>F</given-names></name><article-title>Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>166</volume><fpage>809</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1164/rccm.2107031</pub-id><pub-id pub-id-type="pmid">12231489</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Chailleux</surname><given-names>E</given-names></name><name><surname>Laaban</surname><given-names>JP</given-names></name><name><surname>Veale</surname><given-names>D</given-names></name><article-title>Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: data from the ANTADIR observatory</article-title><source>Chest</source><year>2003</year><volume>123</volume><fpage>1460</fpage><lpage>1466</lpage><pub-id pub-id-type="doi">10.1378/chest.123.5.1460</pub-id><pub-id pub-id-type="pmid">12740261</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="other"><name><surname>De Benedetto</surname><given-names>F</given-names></name><name><surname>Del Ponte</surname><given-names>A</given-names></name><name><surname>Cervone</surname><given-names>L</given-names></name><name><surname>Cisternino</surname><given-names>R</given-names></name><name><surname>Marinari</surname><given-names>S</given-names></name><name><surname>Sbrogia</surname><given-names>M</given-names></name><article-title>Is any relationship between body weight and severity of COPD? Retrospective large population study</article-title><source>Am Rev Respir Dis</source><year>1990</year><issue>suppl. 141</issue><fpage>A35</fpage></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><collab>American Thoracic Society/European Respiratory Society</collab><article-title>Skeletal muscle dysfunction in chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>159</volume><fpage>S1</fpage><lpage>S40</lpage><pub-id pub-id-type="pmid">10194189</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Decramer</surname><given-names>M</given-names></name><name><surname>De Benedetto</surname><given-names>F</given-names></name><name><surname>Del Ponte</surname><given-names>A</given-names></name><name><surname>Marinari</surname><given-names>S</given-names></name><article-title>Systemic effects of COPD</article-title><source>Respir Med</source><year>2005</year><volume>99</volume><issue>Suppl B</issue><fpage>S3</fpage><lpage>S10</lpage><pub-id pub-id-type="pmid">16219454</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>De Benedetto</surname><given-names>F</given-names></name><name><surname>Bitti</surname><given-names>G</given-names></name><name><surname>D’Intino</surname><given-names>D</given-names></name><name><surname>Marinari</surname><given-names>S</given-names></name><name><surname>Del Ponte</surname><given-names>A</given-names></name><article-title>Body weight alone is not an index of nutritional imbalance in the natural course of chronic obstructive lung disease</article-title><source>Monaldi Arch. Chest Dis</source><year>1993</year><volume>48</volume><issue>5</issue><fpage>541</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">8312922</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Prescott</surname><given-names>E</given-names></name><name><surname>Almdal</surname><given-names>T</given-names></name><name><surname>Morten Dahl</surname><given-names>N</given-names></name><name><surname>Andersen</surname><given-names>T</given-names></name><name><surname>Sorensen</surname><given-names>A</given-names></name><name><surname>Lange</surname><given-names>A</given-names></name><article-title>Body Mass, Fat-Free Body Mass and prognosis in patients with chronic Obstructive pulmonary disease from a random population sample</article-title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>173</volume><fpage>79</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">16368793</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Schols</surname><given-names>AM</given-names></name><article-title>Pulmonary cachexia</article-title><source>Int J Cardiol</source><year>2002</year><volume>85</volume><fpage>101</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/S0167-5273(02)00238-3</pub-id><pub-id pub-id-type="pmid">12163214</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Broekhuizen</surname><given-names>R</given-names></name><name><surname>Grimble</surname><given-names>RF</given-names></name><name><surname>Howell</surname><given-names>WM</given-names></name><name><surname>Shale</surname><given-names>DJ</given-names></name><name><surname>Creutzberg</surname><given-names>EC</given-names></name><name><surname>Wouters</surname><given-names>EF</given-names></name><name><surname>Schols</surname><given-names>AM</given-names></name><article-title>Pulmonary cachexia, systemic inflammatory profile, and the interleukin 1β-511 single nucleotide polymorphism</article-title><source>Am J Clin Nutr</source><year>2005</year><volume>82</volume><fpage>1059</fpage><lpage>1064</lpage><pub-id pub-id-type="pmid">16280439</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Hopkinson</surname><given-names>NS</given-names></name><name><surname>Eleftheriou</surname><given-names>KI</given-names></name><name><surname>Payne</surname><given-names>J</given-names></name><name><surname>Nickol</surname><given-names>AH</given-names></name><name><surname>Hawe</surname><given-names>E</given-names></name><name><surname>Moxham</surname><given-names>J</given-names></name><name><surname>Montgomery</surname><given-names>H</given-names></name><name><surname>Polkey</surname><given-names>MI</given-names></name><article-title>+9/+9 Homozygosity of the bradykinin receptor gene polymorphism is associated with reduced fat-free mass in chronic obstructive pulmonary disease</article-title><source>Am J Clin Nutr</source><year>2006</year><volume>83</volume><fpage>912</fpage><lpage>917</lpage><pub-id pub-id-type="pmid">16600946</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Langen</surname><given-names>RCJ</given-names></name><name><surname>Schols</surname><given-names>AMWJ</given-names></name><name><surname>Kelders</surname><given-names>MCJM</given-names></name><name><surname>Van der Velden</surname><given-names>JLJ</given-names></name><name><surname>Wouters</surname><given-names>EFM</given-names></name><name><surname>Janssen-Heininger</surname><given-names>YMW</given-names></name><article-title>Muscle wasting and impaired muscle regeneration in a murine model of chronic pulmonary inflammation</article-title><source>Am J Respir Cell Mol Biol</source><year>2006</year><volume>35</volume><fpage>689</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2006-0103OC</pub-id><pub-id pub-id-type="pmid">16794259</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Sergi</surname><given-names>G</given-names></name><name><surname>Coin</surname><given-names>A</given-names></name><name><surname>Marin</surname><given-names>S</given-names></name><name><surname>Vianello</surname><given-names>A</given-names></name><name><surname>Manzan</surname><given-names>A</given-names></name><name><surname>Peruzza</surname><given-names>S</given-names></name><name><surname>Inelmen</surname><given-names>EM</given-names></name><name><surname>Busetto</surname><given-names>L</given-names></name><name><surname>Mulone</surname><given-names>S</given-names></name><name><surname>Enzi</surname><given-names>G</given-names></name><article-title>Body composition and resting energy expenditure in elderly male patients with chronic obstructive pulmonary disease</article-title><source>Respir Med</source><year>2006</year><volume>100</volume><fpage>1918</fpage><lpage>1924</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2006.03.008</pub-id><pub-id pub-id-type="pmid">16635565</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Wagner</surname><given-names>PD</given-names></name><article-title>Possible mechanisms underlying the development of cachexia in COPD</article-title><source>Eur Respir J</source><year>2008</year><volume>31</volume><fpage>492</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1183/09031936.00074807</pub-id><pub-id pub-id-type="pmid">18310396</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Takabatake</surname><given-names>N</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Abe</surname><given-names>S</given-names></name><name><surname>Hino</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Yuki</surname><given-names>H</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name><name><surname>Tomoike</surname><given-names>H</given-names></name><article-title>Circulating leptin in patients with chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>159</volume><fpage>1215</fpage><lpage>1219</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.159.4.9806134</pub-id><pub-id pub-id-type="pmid">10194168</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Takabatake</surname><given-names>N</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Minamihaba</surname><given-names>O</given-names></name><name><surname>Inage</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>S</given-names></name><name><surname>Kagaya</surname><given-names>S</given-names></name><name><surname>Yamaki</surname><given-names>M</given-names></name><name><surname>Tomoike</surname><given-names>H</given-names></name><article-title>A novel pathophysiologic phenomenon in chachexic patients with chronic obstructive pulmonary disease: the relationship between the circadian rhythm of circulating leptin and the very low-frequency component of heart rate variability</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>163</volume><fpage>1314</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.163.6.2004175</pub-id><pub-id pub-id-type="pmid">11371394</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Di Francia</surname><given-names>M</given-names></name><name><surname>Barbier</surname><given-names>D</given-names></name><name><surname>Mege</surname><given-names>JL</given-names></name><name><surname>Orehek</surname><given-names>J</given-names></name><article-title>Tumor necrosis factor-α levels and weight loss in chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>1994</year><volume>150</volume><fpage>1453</fpage><lpage>1455</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.150.5.7952575</pub-id><pub-id pub-id-type="pmid">7952575</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Eid</surname><given-names>AA</given-names></name><name><surname>Ionescu</surname><given-names>AA</given-names></name><name><surname>Nixon</surname><given-names>LS</given-names></name><name><surname>Lewis-Jenkins</surname><given-names>V</given-names></name><name><surname>Matthews</surname><given-names>SB</given-names></name><name><surname>Griffiths</surname><given-names>TL</given-names></name><name><surname>Shale</surname><given-names>DJ</given-names></name><article-title>Inflammatory response and body composition in chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>164</volume><fpage>1414</fpage><lpage>1418</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.164.8.2008109</pub-id><pub-id pub-id-type="pmid">11704588</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Itoh</surname><given-names>T</given-names></name><name><surname>Nagaya</surname><given-names>N</given-names></name><name><surname>Yoshikawa</surname><given-names>M</given-names></name><name><surname>Fukuoka</surname><given-names>A</given-names></name><name><surname>Takenaka</surname><given-names>H</given-names></name><name><surname>Shimizu</surname><given-names>Y</given-names></name><name><surname>Haruta</surname><given-names>Y</given-names></name><name><surname>Oya</surname><given-names>H</given-names></name><name><surname>Yamagishi</surname><given-names>M</given-names></name><name><surname>Hosoda</surname><given-names>H</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>H</given-names></name><article-title>Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2004</year><volume>170</volume><fpage>879</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1164/rccm.200310-1404OC</pub-id><pub-id pub-id-type="pmid">15271696</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Schols</surname><given-names>AMWJ</given-names></name><name><surname>Crutzberg</surname><given-names>EC</given-names></name><name><surname>Buurman</surname><given-names>WA</given-names></name><name><surname>Campfield</surname><given-names>LA</given-names></name><name><surname>Saris</surname><given-names>WHM</given-names></name><name><surname>Wouters</surname><given-names>EFM</given-names></name><article-title>Plasma leptin is related to proinflammatory staus and dietary intake in patients with chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>160</volume><fpage>1220</fpage><lpage>1226</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.160.4.9811033</pub-id><pub-id pub-id-type="pmid">10508810</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Antonucci</surname><given-names>R</given-names></name><name><surname>Berton</surname><given-names>E</given-names></name><name><surname>Huertas</surname><given-names>P</given-names></name><name><surname>Laveneziana</surname><given-names>P</given-names></name><name><surname>Palange</surname><given-names>P</given-names></name><article-title>Exercise physiology in COPD</article-title><source>Monaldi Arch Chest Dis</source><year>2003</year><volume>59</volume><issue>2</issue><fpage>134</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">14635502</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Koechlin</surname><given-names>C</given-names></name><name><surname>Couillard</surname><given-names>A</given-names></name><name><surname>Simar</surname><given-names>D</given-names></name><name><surname>Cristol</surname><given-names>JP</given-names></name><name><surname>Bellet</surname><given-names>H</given-names></name><name><surname>Hayot</surname><given-names>M</given-names></name><name><surname>Prefaut</surname><given-names>C</given-names></name><article-title>Does oxidative stress alter quadriceps endurance in chronic obstructive pulmonary disease?</article-title><source>Am J Respir Crit Care Med</source><year>2004</year><volume>169</volume><fpage>1022</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1164/rccm.200310-1465OC</pub-id><pub-id pub-id-type="pmid">15001462</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Gosker</surname><given-names>HR</given-names></name><name><surname>Lencer</surname><given-names>NH</given-names></name><name><surname>Franssen</surname><given-names>FM</given-names></name><name><surname>Van der Vusse</surname><given-names>GJ</given-names></name><name><surname>Wouters</surname><given-names>EF</given-names></name><name><surname>Schols</surname><given-names>AM</given-names></name><article-title>Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD</article-title><source>Chest</source><year>2003</year><volume>123</volume><fpage>1416</fpage><lpage>1424</lpage><pub-id pub-id-type="doi">10.1378/chest.123.5.1416</pub-id><pub-id pub-id-type="pmid">12740256</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Vogiatzis</surname><given-names>I</given-names></name><name><surname>Simoes</surname><given-names>DC</given-names></name><name><surname>Stratakos</surname><given-names>G</given-names></name><name><surname>Kourepini</surname><given-names>E</given-names></name><name><surname>Terzia</surname><given-names>G</given-names></name><name><surname>Manta</surname><given-names>P</given-names></name><name><surname>Athanasopoulos</surname><given-names>D</given-names></name><name><surname>Roussos</surname><given-names>C</given-names></name><name><surname>Wagner</surname><given-names>PD</given-names></name><name><surname>Zakynthinos</surname><given-names>S</given-names></name><article-title>Effect of pulmonary rehabilitation on muscle remodelling in cachectic patients with COPD</article-title><source>Eur Respir J</source><year>2010</year><volume>36</volume><fpage>301</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1183/09031936.00112909</pub-id><pub-id pub-id-type="pmid">20110400</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Rutten</surname><given-names>EP</given-names></name><name><surname>Franssen</surname><given-names>FM</given-names></name><name><surname>Engelen</surname><given-names>MP</given-names></name><name><surname>Wouters</surname><given-names>EF</given-names></name><name><surname>Deutz</surname><given-names>NE</given-names></name><name><surname>Schols</surname><given-names>AM</given-names></name><article-title>Greater whole-body myofibrillar protein breakdown in cachectic patients with chronic obstructive pulmonary disease</article-title><source>Am J Clin Nutr</source><year>2006</year><volume>83</volume><fpage>829</fpage><lpage>834</lpage><pub-id pub-id-type="pmid">16600935</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Couillard</surname><given-names>A</given-names></name><name><surname>Koechlin</surname><given-names>C</given-names></name><name><surname>Cristol</surname><given-names>JP</given-names></name><name><surname>Varray</surname><given-names>A</given-names></name><name><surname>Prefaut</surname><given-names>C</given-names></name><article-title>Evidence of local exercise- induced systemic oxidative stress in chronic obstructive pulmonary disease</article-title><source>Eur Respir J</source><year>2002</year><volume>20</volume><fpage>1123</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.1183/09031936.02.00014302</pub-id><pub-id pub-id-type="pmid">12449164</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Sahebjami</surname><given-names>H</given-names></name><name><surname>Sathianpitayakul</surname><given-names>E</given-names></name><article-title>Influence of body weight on the severity of dyspnea in chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2000</year><volume>161</volume><fpage>886</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.161.3.9905023</pub-id><pub-id pub-id-type="pmid">10712338</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Naimi</surname><given-names>AI</given-names></name><name><surname>Bourbeau</surname><given-names>J</given-names></name><name><surname>Perrault</surname><given-names>H</given-names></name><name><surname>Baril</surname><given-names>J</given-names></name><name><surname>Wright-Paradis</surname><given-names>C</given-names></name><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>Taivassalo</surname><given-names>T</given-names></name><name><surname>Sheel</surname><given-names>AW</given-names></name><name><surname>Rabøl</surname><given-names>R</given-names></name><name><surname>Dela</surname><given-names>F</given-names></name><name><surname>Boushel</surname><given-names>R</given-names></name><article-title>Altered mitochondrial regulation in quadriceps muscles of patients with COPD</article-title><source>Clin Physiol Funct Imaging</source><year>2011</year><volume>31</volume><issue>2</issue><fpage>124</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">21091605</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Puente-Maestu</surname><given-names>L</given-names></name><name><surname>Pérez-Parra</surname><given-names>J</given-names></name><name><surname>Godoy</surname><given-names>R</given-names></name><name><surname>Moreno</surname><given-names>N</given-names></name><name><surname>Tejedor</surname><given-names>A</given-names></name><name><surname>González-Aragoneses</surname><given-names>F</given-names></name><name><surname>Bravo</surname><given-names>JL</given-names></name><name><surname>Alvarez</surname><given-names>FV</given-names></name><name><surname>Camaño</surname><given-names>S</given-names></name><name><surname>Agustí</surname><given-names>A</given-names></name><article-title>Abnormal mitochondrial function in locomotor and respiratory muscles of COPD patients</article-title><source>Eur Respir J</source><year>2009</year><volume>33</volume><issue>5</issue><fpage>1045</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1183/09031936.00112408</pub-id><pub-id pub-id-type="pmid">19129279</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Slebos</surname><given-names>DJ</given-names></name><name><surname>Van der Toorn</surname><given-names>M</given-names></name><name><surname>Bakker</surname><given-names>SJ</given-names></name><name><surname>Kauffman</surname><given-names>HF</given-names></name><article-title>Mitochondrial dysfunction in COPD patients with low body mass index</article-title><source>Eur Respir J</source><year>2007</year><volume>30</volume><issue>3</issue><fpage>600</fpage><comment>author reply 600–1</comment><pub-id pub-id-type="pmid">17766639</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Gosker</surname><given-names>HR</given-names></name><name><surname>Hesselink</surname><given-names>MK</given-names></name><name><surname>Duimel</surname><given-names>H</given-names></name><name><surname>Ward</surname><given-names>KA</given-names></name><name><surname>Schols</surname><given-names>AM</given-names></name><article-title>Reduced mitochondrial density in the vastus lateralis muscle of patients with COPD</article-title><source>Eur Respir J</source><year>2007</year><volume>30</volume><issue>1</issue><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1183/09031936.00146906</pub-id><pub-id pub-id-type="pmid">17428811</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Rabinovich</surname><given-names>RA</given-names></name><name><surname>Bastos</surname><given-names>R</given-names></name><name><surname>Ardite</surname><given-names>E</given-names></name><name><surname>Llinàs</surname><given-names>L</given-names></name><name><surname>Orozco-Levi</surname><given-names>M</given-names></name><name><surname>Gea</surname><given-names>J</given-names></name><name><surname>Vilaró</surname><given-names>J</given-names></name><name><surname>Barberà</surname><given-names>JA</given-names></name><name><surname>Rodríguez-Roisin</surname><given-names>R</given-names></name><name><surname>Fernández-Checa</surname><given-names>JC</given-names></name><name><surname>Roca</surname><given-names>J</given-names></name><article-title>Mitochondrial dysfunction in COPD patients with low body mass index</article-title><source>Eur Respir J</source><year>2007</year><volume>29</volume><issue>4</issue><fpage>643</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1183/09031936.00086306</pub-id><pub-id pub-id-type="pmid">17182653</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Pajen</surname><given-names>JF</given-names></name><name><surname>Wuyam</surname><given-names>B</given-names></name><name><surname>Levy</surname><given-names>P</given-names></name><name><surname>Reutenauer</surname><given-names>H</given-names></name><name><surname>Stieglitz</surname><given-names>P</given-names></name><name><surname>Paramelle</surname><given-names>B</given-names></name><name><surname>Le Bas</surname><given-names>JF</given-names></name><article-title>Muscular metabolism during oxygen supplementation in patients with chronic hypoxemia</article-title><source>Am Rev Respir Dis</source><year>1993</year><volume>147</volume><fpage>592</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1164/ajrccm/147.3.592</pub-id><pub-id pub-id-type="pmid">8442592</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Faager</surname><given-names>G</given-names></name><name><surname>Söderlund</surname><given-names>K</given-names></name><name><surname>Sköld</surname><given-names>CM</given-names></name><name><surname>Rundgren</surname><given-names>S</given-names></name><name><surname>Tollbäck</surname><given-names>A</given-names></name><name><surname>Jakobsson</surname><given-names>P</given-names></name><article-title>Creatine supplementation and physical training in patients with COPD: a double blind, placebo-controlled study</article-title><source>Int J Chron Obstruct Pulmon Dis</source><year>2006</year><volume>1</volume><issue>4</issue><fpage>445</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">18044100</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Tanrikulu</surname><given-names>AC</given-names></name><name><surname>Abakay</surname><given-names>A</given-names></name><name><surname>Evliyaoglu</surname><given-names>O</given-names></name><name><surname>Palanci</surname><given-names>Y</given-names></name><article-title>Coenzyme Q10, copper, zinc, and lipid peroxidation levels in serum of patients with chronic obstructive pulmonary disease</article-title><source>Biol Trace Elem Res</source><year>2011</year><volume>143</volume><issue>2</issue><fpage>659</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1007/s12011-010-8897-5</pub-id><pub-id pub-id-type="pmid">21080098</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Seo</surname><given-names>AY</given-names></name><name><surname>Vorobyeva</surname><given-names>DA</given-names></name><name><surname>Carter</surname><given-names>CS</given-names></name><name><surname>Anton</surname><given-names>SD</given-names></name><name><surname>Lezza</surname><given-names>AM</given-names></name><name><surname>Leeuwenburgh</surname><given-names>C</given-names></name><article-title>Beneficial effects of a Q-ter based nutritional mixture on functional performance, mitochondrial function, and oxidative stress in rats</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><fpage>e10572</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0010572</pub-id><pub-id pub-id-type="pmid">20485503</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Saremi</surname><given-names>A</given-names></name><name><surname>Gharakhanloo</surname><given-names>R</given-names></name><name><surname>Sharghi</surname><given-names>S</given-names></name><name><surname>Gharaati</surname><given-names>MR</given-names></name><name><surname>Larijani</surname><given-names>B</given-names></name><name><surname>Omidfar</surname><given-names>K</given-names></name><article-title>Effects of oral creatine and resistance training on serum myostatin and GASP-1</article-title><source>Mol Cell Endocrinol</source><year>2010</year><volume>317</volume><issue>1–2</issue><fpage>25</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">20026378</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Guarducci</surname><given-names>L</given-names></name><name><surname>Fumagalli</surname><given-names>S</given-names></name><name><surname>Sforza</surname><given-names>G</given-names></name><name><surname>Fattirolli</surname><given-names>N</given-names></name><name><surname>Marchionni</surname><given-names>G</given-names></name><article-title>Effetti di un associazione di Coenzima Q10 e creatina sulla tolleranza all’esercizio fisico e sulla qualità della vita di pazienti con scompenso cardiaco</article-title><source>G Gerontol</source><year>2006</year><volume>5</volume><fpage>499</fpage></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Fumagalli</surname><given-names>S</given-names></name><name><surname>Fattirolli</surname><given-names>F</given-names></name><name><surname>Guarducci</surname><given-names>L</given-names></name><name><surname>Cellai</surname><given-names>T</given-names></name><name><surname>Baldasseroni</surname><given-names>S</given-names></name><name><surname>Tarantini</surname><given-names>F</given-names></name><name><surname>Di Bari</surname><given-names>M</given-names></name><name><surname>Masotti</surname><given-names>G</given-names></name><name><surname>Marchionni</surname><given-names>N</given-names></name><article-title>Coenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo controlled, double-blind study</article-title><source>Clin Cardiol</source><year>2011</year><volume>34</volume><fpage>211</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1002/clc.20846</pub-id><pub-id pub-id-type="pmid">21462215</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Fuld</surname><given-names>JP</given-names></name><name><surname>Kilduff</surname><given-names>LP</given-names></name><name><surname>Neder</surname><given-names>JA</given-names></name><name><surname>Pitsiladis</surname><given-names>Y</given-names></name><name><surname>Lean</surname><given-names>MEJ</given-names></name><name><surname>Ward</surname><given-names>SA</given-names></name><name><surname>Cotton</surname><given-names>MM</given-names></name><article-title>Creatine supplementation during pulmonary rehabilitation in chronic obstructive pulmonary disease</article-title><source>Thorax</source><year>2005</year><volume>60</volume><fpage>531</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1136/thx.2004.030452</pub-id><pub-id pub-id-type="pmid">15994258</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Bartlett</surname><given-names>HR</given-names></name><name><surname>Puhl</surname><given-names>SM</given-names></name><name><surname>Hdgson</surname><given-names>L</given-names></name><name><surname>Buskirk</surname><given-names>ER</given-names></name><article-title>Fat-free mass in relation to stature: ratios of fat-free mass to height in children, adults end elderly subjects</article-title><source>Am J Clin Nutr</source><year>1991</year><volume>53</volume><fpage>1112</fpage><lpage>1116</lpage><pub-id pub-id-type="pmid">2021121</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Katz</surname><given-names>TF</given-names></name><article-title>A.D.L. Activities of Daily Living</article-title><source>JAMA</source><year>1963</year><volume>185</volume><fpage>914</fpage><pub-id pub-id-type="doi">10.1001/jama.1963.03060120024016</pub-id><pub-id pub-id-type="pmid">14044222</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Statement</surname><given-names>ATS</given-names></name><article-title>Guidelines for the Six-Minute Walk Test</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>166</volume><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">12091180</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>PW</given-names></name><name><surname>Quirk</surname><given-names>FH</given-names></name><name><surname>Baveystock</surname><given-names>CM</given-names></name><article-title>The St George's Respiratory Questionnaire</article-title><source>Respir Med</source><year>1991</year><volume>85</volume><issue>suppl</issue><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">1759018</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Çalıkoglu</surname><given-names>M</given-names></name><name><surname>Şahin</surname><given-names>G</given-names></name><name><surname>Unlu</surname><given-names>A</given-names></name><name><surname>Ozturk</surname><given-names>C</given-names></name><name><surname>Tamer</surname><given-names>L</given-names></name><name><surname>Ercan</surname><given-names>B</given-names></name><name><surname>Kanik</surname><given-names>A</given-names></name><name><surname>Atik</surname><given-names>U</given-names></name><article-title>Leptin and TNF-Alpha Levels in Patients with Chronic Obstructive Pulmonary Disease and Their Relationship to Nutritional Parameters</article-title><source>Respiration</source><year>2004</year><volume>71</volume><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1159/000075648</pub-id><pub-id pub-id-type="pmid">14872110</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Alway</surname><given-names>SE</given-names></name><name><surname>Swisher</surname><given-names>A</given-names></name><name><surname>Siu</surname><given-names>PM</given-names></name><article-title>Increased expression of apoptotic genes in the diaphragm and soleus muscle of the emphysematous hamster</article-title><source>Faseb J</source><year>2004</year><volume>18</volume><fpage>A358</fpage></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Bernard</surname><given-names>S</given-names></name><name><surname>LeBlanc</surname><given-names>P</given-names></name><name><surname>Whittom</surname><given-names>F</given-names></name><name><surname>Carrier</surname><given-names>G</given-names></name><name><surname>Jobin</surname><given-names>J</given-names></name><name><surname>Belleau</surname><given-names>R</given-names></name><name><surname>Maltais</surname><given-names>F</given-names></name><article-title>Peripheral muscle weakness in patients with chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>1998</year><volume>158</volume><fpage>629</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.158.2.9711023</pub-id><pub-id pub-id-type="pmid">9700144</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Gosker</surname><given-names>HR</given-names></name><name><surname>Kubat</surname><given-names>B</given-names></name><name><surname>Schaart</surname><given-names>G</given-names></name><name><surname>Van der Vusse</surname><given-names>GJ</given-names></name><name><surname>Wouters</surname><given-names>EF</given-names></name><name><surname>Schols</surname><given-names>AM</given-names></name><article-title>Myopathological features in skeletal muscle of patients with chronic obstructive pulmonary disease</article-title><source>Eur Respir J</source><year>2003</year><volume>22</volume><issue>2</issue><fpage>280</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1183/09031936.03.00012803</pub-id><pub-id pub-id-type="pmid">12952261</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Palange</surname><given-names>P</given-names></name><name><surname>Forte</surname><given-names>S</given-names></name><name><surname>Onorati</surname><given-names>P</given-names></name><name><surname>Paravati</surname><given-names>V</given-names></name><name><surname>Manfredi</surname><given-names>F</given-names></name><name><surname>Serra</surname><given-names>P</given-names></name><name><surname>Carlone</surname><given-names>S</given-names></name><article-title>Effect of reduced body weight on muscle aerobic capacity in patients with COPD</article-title><source>Chest</source><year>1998</year><volume>114</volume><issue>1</issue><fpage>12</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1378/chest.114.1.12</pub-id><pub-id pub-id-type="pmid">9674441</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Rabinovich</surname><given-names>RA</given-names></name><name><surname>Vilaró</surname><given-names>J</given-names></name><article-title>Structural and functional changes of peripheral muscles in chronic obstructive pulmonary disease patients</article-title><source>Curr Opin Pulm Med</source><year>2010</year><volume>16</volume><issue>2</issue><fpage>123</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1097/MCP.0b013e328336438d</pub-id><pub-id pub-id-type="pmid">20071991</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><name><surname>Ribera</surname><given-names>F</given-names></name><name><surname>N'Guessan</surname><given-names>B</given-names></name><name><surname>Zoll</surname><given-names>J</given-names></name><name><surname>Fortin</surname><given-names>D</given-names></name><name><surname>Serrurier</surname><given-names>B</given-names></name><name><surname>Mettauer</surname><given-names>B</given-names></name><name><surname>Bigard</surname><given-names>X</given-names></name><name><surname>Ventura-Clapier</surname><given-names>R</given-names></name><name><surname>Lampert</surname><given-names>E</given-names></name><article-title>Mitochondrial electron transport chain function is enhanced in inspiratory muscles of patients with chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2003</year><volume>167</volume><issue>6</issue><fpage>873</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1164/rccm.200206-519OC</pub-id><pub-id pub-id-type="pmid">12493645</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><name><surname>Hamaoka</surname><given-names>T</given-names></name><name><surname>Tatsumi</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Arai</surname><given-names>Y</given-names></name><name><surname>Horie</surname><given-names>Y</given-names></name><name><surname>Masuyama</surname><given-names>S</given-names></name><name><surname>Tanabe</surname><given-names>N</given-names></name><name><surname>Takiguchi</surname><given-names>Y</given-names></name><name><surname>Ikehira</surname><given-names>H</given-names></name><name><surname>Obata</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Tanada</surname><given-names>S</given-names></name><name><surname>Kuriyama</surname><given-names>T</given-names></name><article-title>Metabolic activity in skeletal muscles of patients with non-hypoxaemic chronic obstructive pulmonary disease studied by 31P-magnetic resonance spectroscopy</article-title><source>Respirology</source><year>2005</year><volume>10</volume><issue>2</issue><fpage>164</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1843.2005.00696.x</pub-id><pub-id pub-id-type="pmid">15823180</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><name><surname>Layec</surname><given-names>G</given-names></name><name><surname>Haseler</surname><given-names>LJ</given-names></name><name><surname>Richardson</surname><given-names>RS</given-names></name><article-title>The effect of higher ATP cost of contraction on the metabolic response to graded exercise in patients with chronic obstructive pulmonary disease</article-title><source>J Appl Physiol</source><year>2012</year><volume>112</volume><issue>6</issue><fpage>1041</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.00986.2011</pub-id><pub-id pub-id-type="pmid">22174392</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><name><surname>Picard</surname><given-names>M</given-names></name><name><surname>Godin</surname><given-names>R</given-names></name><name><surname>Sinnreich</surname><given-names>M</given-names></name><name><surname>Baril</surname><given-names>J</given-names></name><name><surname>Bourbeau</surname><given-names>J</given-names></name><name><surname>Perrault</surname><given-names>H</given-names></name><name><surname>Taivassalo</surname><given-names>T</given-names></name><name><surname>Burelle</surname><given-names>Y</given-names></name><article-title>The mitochondrial phenotype of peripheral muscle in chronic obstructive pulmonary disease: disuse or dysfunction?</article-title><source>Am J Respir Crit Care Med</source><year>2008</year><volume>178</volume><issue>10</issue><fpage>1040</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1164/rccm.200807-1005OC</pub-id><pub-id pub-id-type="pmid">18755922</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><name><surname>Creutzberg</surname><given-names>EC</given-names></name><name><surname>Wouters</surname><given-names>EF</given-names></name><name><surname>Mastert</surname><given-names>R</given-names></name><name><surname>Weling-Scheepers</surname><given-names>CA</given-names></name><name><surname>Schols</surname><given-names>AM</given-names></name><article-title>Efficacy of nutritional supplementation therapy in depleted patients with chronic obstructive pulmonary disease</article-title><source>Nutrition</source><year>2003</year><volume>19</volume><fpage>120</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/S0899-9007(02)00841-9</pub-id><pub-id pub-id-type="pmid">12591542</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><name><surname>Cai</surname><given-names>BJ</given-names></name><name><surname>Zhu</surname><given-names>YY</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>ZZ</given-names></name><name><surname>Zao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Gail</surname><given-names>M</given-names></name><name><surname>Comer</surname><given-names>GM</given-names></name><article-title>Effect of supplementing a high-fat, low-carbohydrate enteral formula in COPD patients</article-title><source>Nutrition</source><year>2003</year><volume>19</volume><issue>3</issue><fpage>229</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/S0899-9007(02)01064-X</pub-id><pub-id pub-id-type="pmid">12620524</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><name><surname>Ferreira</surname><given-names>IM</given-names></name><name><surname>Brooks</surname><given-names>D</given-names></name><name><surname>Lacasse</surname><given-names>Y</given-names></name><name><surname>Goldstein</surname><given-names>RS</given-names></name><name><surname>White</surname><given-names>J</given-names></name><article-title>Nutritional supplementation for stable chronic obstructive pulmonary disease</article-title><source>Cochrane Database Syst Rev</source><year>2005</year><volume>18</volume><issue>2</issue><fpage>CD000998</fpage><pub-id pub-id-type="pmid">15846608</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><name><surname>Steinert</surname><given-names>MC</given-names></name><name><surname>Barton</surname><given-names>L</given-names></name><name><surname>Singh</surname><given-names>SJ</given-names></name><name><surname>Morgan</surname><given-names>MD</given-names></name><article-title>Nutritional enhancement of exercise performance in chronic obstructive pulmonary disease: a randomised controlled trial</article-title><source>Thorax</source><year>2003</year><volume>58</volume><fpage>745751</fpage></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><name><surname>Engelen</surname><given-names>MP</given-names></name><name><surname>Rutten</surname><given-names>EP</given-names></name><name><surname>De Castro</surname><given-names>CL</given-names></name><name><surname>Wouters</surname><given-names>EF</given-names></name><name><surname>Schols</surname><given-names>AM</given-names></name><name><surname>Deutz</surname><given-names>NE</given-names></name><article-title>Casein protein results in higher prandial and exercise induced whole body protein anabolism than whey protein in chronic obstructive pulmonary disease</article-title><source>Metabolism</source><year>2012</year><volume>61</volume><issue>9</issue><fpage>1289</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2012.03.001</pub-id><pub-id pub-id-type="pmid">22512824</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><name><surname>Engelen</surname><given-names>MP</given-names></name><name><surname>De De Castro</surname><given-names>CL</given-names></name><name><surname>Rutten</surname><given-names>EP</given-names></name><name><surname>Wouters</surname><given-names>EF</given-names></name><name><surname>Schols</surname><given-names>AM</given-names></name><name><surname>Deutz</surname><given-names>NE</given-names></name><article-title>Enhanced anabolic response to milk protein sip feeding in elderly subjects with COPD is associated with a reduced splanchnic extraction of multiple amino acids</article-title><source>Clin Nutr</source><year>2012</year><volume>31</volume><issue>5</issue><fpage>616</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2012.04.006</pub-id><pub-id pub-id-type="pmid">22682082</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><name><surname>Dal Negro</surname><given-names>RW</given-names></name><name><surname>Testa</surname><given-names>A</given-names></name><name><surname>Aquilani</surname><given-names>R</given-names></name><name><surname>Tognella</surname><given-names>S</given-names></name><name><surname>Pasini</surname><given-names>E</given-names></name><name><surname>Barbieri</surname><given-names>A</given-names></name><name><surname>Boschi</surname><given-names>F</given-names></name><article-title>Essential amino acid supplementation in patients with severe COPD:a step towards home rehabilitation</article-title><source>Monaldi Arch Chest Dis</source><year>2012</year><volume>77</volume><issue>2</issue><fpage>67</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">23193843</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><name><surname>Baldi</surname><given-names>S</given-names></name><name><surname>Aquilani</surname><given-names>R</given-names></name><name><surname>Pinna</surname><given-names>GD</given-names></name><name><surname>Poggi</surname><given-names>P</given-names></name><name><surname>De Martini</surname><given-names>A</given-names></name><name><surname>Bruschi</surname><given-names>C</given-names></name><article-title>Fat-free mass change after nutritional rehabilitation in weight losing COPD: role of insulin C-reactive protein and tissue hypoxia</article-title><source>Int J Chron Obstruct Pulm Dis</source><year>2010</year><volume>5</volume><fpage>2939</fpage></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><name><surname>Pansarasa</surname><given-names>O</given-names></name><name><surname>Flati</surname><given-names>V</given-names></name><name><surname>Corsett</surname><given-names>G</given-names></name><name><surname>Brocca</surname><given-names>L</given-names></name><article-title>Oral Amino AcidSupplementation Counteracts Age-Induced Sarcopenia in Elderly Rats</article-title><source>Am J Cardiol</source><year>2008</year><volume>102</volume><fpage>S35</fpage><lpage>41</lpage></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><name><surname>Allard</surname><given-names>ML</given-names></name><name><surname>Jeejeebhoy</surname><given-names>KN</given-names></name><name><surname>Sole</surname><given-names>MJ</given-names></name><article-title>The management of conditioned nutritional requirements in heart failure</article-title><source>Heart Fail Rev</source><year>2006</year><volume>11</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1007/s10741-006-9195-3</pub-id><pub-id pub-id-type="pmid">16819580</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><name><surname>Witte</surname><given-names>KK</given-names></name><name><surname>Clark</surname><given-names>AL</given-names></name><article-title>Micronutrients and their supplementation in chronic cardiac failure: an update beyond theoretical perspectives</article-title><source>Heart Fail Rev</source><year>2006</year><volume>11</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1007/s10741-006-9194-4</pub-id><pub-id pub-id-type="pmid">16819579</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><name><surname>Witte</surname><given-names>KK</given-names></name><name><surname>Clark</surname><given-names>AL</given-names></name><name><surname>Cleland</surname><given-names>JG</given-names></name><article-title>Chronic heart failure and micronutrients</article-title><source>J Am Coll Cardiol</source><year>2001</year><volume>37</volume><fpage>1765</fpage><lpage>1774</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(01)01227-X</pub-id><pub-id pub-id-type="pmid">11401109</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><name><surname>Belardinelli</surname><given-names>R</given-names></name><name><surname>Mucaj</surname><given-names>A</given-names></name><name><surname>Lacalaprice</surname><given-names>F</given-names></name><name><surname>Solenghi</surname><given-names>M</given-names></name><name><surname>Principi</surname><given-names>F</given-names></name><name><surname>Tiano</surname><given-names>L</given-names></name><name><surname>Littarru</surname><given-names>GP</given-names></name><article-title>Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure</article-title><source>Biofactors</source><year>2005</year><volume>25</volume><fpage>137</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1002/biof.5520250115</pub-id><pub-id pub-id-type="pmid">16873938</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><name><surname>Belardinelli</surname><given-names>R</given-names></name><name><surname>Muc¸Aj</surname><given-names>A</given-names></name><name><surname>Lacalaprice</surname><given-names>F</given-names></name><name><surname>Solenghi</surname><given-names>M</given-names></name><name><surname>Seddaiu</surname><given-names>G</given-names></name><name><surname>Principi</surname><given-names>F</given-names></name><name><surname>Tiano</surname><given-names>L</given-names></name><name><surname>Littarru</surname><given-names>GP</given-names></name><article-title>Coenzyme Q10 and exercise training in chronic heart failure</article-title><source>Eur Heart J</source><year>2006</year><volume>27</volume><fpage>2675</fpage><lpage>2681</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehl158</pub-id><pub-id pub-id-type="pmid">16882678</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><name><surname>Molyneux</surname><given-names>SL</given-names></name><name><surname>Florkowski</surname><given-names>CM</given-names></name><name><surname>George</surname><given-names>PM</given-names></name><name><surname>Pilbrow</surname><given-names>AP</given-names></name><name><surname>Frampton</surname><given-names>CM</given-names></name><name><surname>Lever</surname><given-names>M</given-names></name><name><surname>Richards</surname><given-names>AM</given-names></name><article-title>Coenzyme Q10: an independent predictor of mortality in chronic heart failure</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>52</volume><fpage>1435</fpage><lpage>1441</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2008.07.044</pub-id><pub-id pub-id-type="pmid">19017509</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><name><surname>Mortensen</surname><given-names>SA</given-names></name><article-title>Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of “Q-symbio”—a multinational trial</article-title><source>Biofactors</source><year>2003</year><volume>18</volume><fpage>79</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1002/biof.5520180210</pub-id><pub-id pub-id-type="pmid">14695923</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><name><surname>Fumagalli</surname><given-names>S</given-names></name><name><surname>Fattirolli</surname><given-names>F</given-names></name><name><surname>Guarducci</surname><given-names>L</given-names></name><name><surname>Cellai</surname><given-names>T</given-names></name><name><surname>Baldasseroni</surname><given-names>S</given-names></name><name><surname>Tarantini</surname><given-names>F</given-names></name><name><surname>Di Bari</surname><given-names>M</given-names></name><name><surname>Masotti</surname><given-names>G</given-names></name><name><surname>Marchionni</surname><given-names>N</given-names></name><article-title>Coenzyme Q10 Terclatrate and Creatine in Chronic Heart Failure: A Randomized, Placebo-Controlled Double-Blind Study</article-title><source>Clin Cardiol</source><year>2011</year><volume>34</volume><issue>4</issue><fpage>211</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1002/clc.20846</pub-id><pub-id pub-id-type="pmid">21462215</pub-id></mixed-citation></ref></ref-list></back></article>